Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study

Kira Trares, MSc^{a,b,c}, Megha Bhardwaj, PhD^b, Laura Perna, PhD^{d,e}, Hannah Stocker, PhD^{a,b,c}, Agnese Petrera, PhD^f, Stefanie M. Hauck, PhD^f, Konrad Beyreuther, PhD^a, Hermann Brenner, MD^{a,b}, Ben Schöttker, PhD, MPH, MSc^{a,b}

^aNetwork Aging Research, Heidelberg University, Bergheimer Straße 20, 69115 Heidelberg, Germany;

^bDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; ^cMedical Faculty, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg;

^dDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Kraepelinstraße 2-10, 80804 Munich, Germany; ^e Division of Mental Health of Older Adults, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, 80336 Munich, Germany; ^fResearch Unit Protein Science and Metabolomics and Proteomics Core Facility, Helmholtz Zentrum Munich - German Research Center for Environmental Health, Heidemannstraße 1, 80939 Munich

Declarations of interest: none.

Laboratory or institution of origin: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Baden-Württemberg, 69120, Heidelberg, Germany

Correspondence to: Ben Schöttker, PhD, Im Neuenheimer Feld 581, 69120, Heidelberg, Germany, Tel.: +49-6221421355, Fax: +49-6221421302, E-mail: b.schoettker@dkfz.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Word count: 2999

Key Points

Question: Which biomarkers of the inflammatory proteome are risk factors for dementia?

Findings: After correction for multiple testing, in this large prospective cohort study (n=1,782), 58 of 72 tested (80.6%) inflammation-related proteins were associated with all-cause dementia. Furthermore, 22 and 33 were significantly associated with Alzheimer's disease and vascular dementia. Due to high inter-correlation, only four biomarkers (CX3CL1, EN-RAGE, LAP TGF-beta-1, VEGF-A) were independently associated with dementia outcomes.

Meaning: The underlying pathophysiology of dementia development might involve complex inflammatory protein clusters, and the identified biomarkers might be promising new drug targets, early diagnostic markers, or parts of prediction models.

Abstract

Importance: Chronic inflammation is increasingly recognized as a central feature of several forms of dementia.

Objective: To determine which biomarkers of the inflammation-related proteome are associated with all-cause dementia, Alzheimer’s disease (AD), or vascular dementia (VD).

Design: Analyses were performed in a case-cohort study design based on an ongoing German population-based cohort study.

Setting: Serum samples of study participants were collected at baseline (2000-20002), and participants were followed up for 17 years. Information about a dementia diagnosis was collected during follow-up via collection of medical records from general practitioners.

Participants: Ascertainment of potential dementia development during follow-ups was conducted for 6,284 study participants aged 50-75 years at baseline. Biomarker measurements were performed in a randomly collected sample of 1,435 participants and all incident dementia cases of the rest of the cohort (n=393).

Main Outcomes and Measures: All-cause dementia, AD and VD were the primary outcomes of this analysis.

Results: Biomarkers were analyzed in 504 all-cause dementia cases (mean age, 67.0 [SD, 5.1] years; 262 female [52.0%], and 242 male [48.0%]) and 1,278 controls (mean age, 61.9 [standard deviation (SD): 6.5] years; 703 female [55.0%], and 575 male [45.0%]). Among the dementia cases, 163 participants developed AD and 195 VD. After correction for multiple testing, 58 biomarkers were statistically significantly associated with all-cause dementia, 22 with AD, and 33 with VD incidence. All analyses were adjusted for potential confounders. Besides single biomarker associations, we identified four biomarker clusters based on the strongest and independently associated biomarkers CX3CL1, EN-RAGE, LAP TGF-beta-1 and VEGF-A. CX3CL1 (Odds ratio [95%-confidence interval] per 1 standard

deviation increase: 1.41 [1.24-1.60]) and EN-RAGE (1.41 [1.25-1.60]) were associated with all-cause dementia incidence, EN-RAGE (1.51 [1.25-1.83]) and LAP TGF-beta-1 (1.46 [1.21-1.76]) with AD incidence, and VEGF-A (1.43 [1.20-1.70]) with VD incidence. All named associations were stronger among *APOE* ϵ 4 negative subjects.

Conclusion and Relevance: This study shows for the first time that the majority of inflammation-related proteins measured in serum samples (58 of 72 tested (80.6%)) are associated with all-cause dementia incidence. Future studies should not only concentrate on single biomarkers but also the complex relationships in biomarker clusters.

1. Introduction

Dementia is a major challenge for global public health and social care systems. As the number of dementia cases increases with rising life expectancy, it has been estimated that almost 75 million people worldwide will live with dementia in 2030¹. Therefore, research on how to prevent or delay the onset of dementia is one of the major challenges globally².

Inflammation likely plays a key role in the development and progression of dementia³. In the brain, inflammatory processes are a defence mechanism against infection, toxins, or injury. However, persistent inflammation might disrupt the equilibrium of pro- and anti-inflammatory signalling. In neuroinflammation, microglia and astrocytes are activated and release various pro-inflammatory products causing chronic inflammation and neurodegeneration^{4,5}. Several studies have found increased levels of pro-inflammatory cytokines and proteins like interleukin-6 (IL-6), interleukin-1 β (IL-1 β), C-reactive protein (CRP), or α 1-antichymotrypsin (α 1-AT) to be associated with the onset of all-cause dementia^{6,7}. Further studies also revealed that CRP, IL-1 β , IL-2, IL-4, IL-6, IL8, IL-10, IL-12, IL-18, monocyte protein-1 (MCP-1), MCP-3, interferon- γ -inducible protein 10 (IP-10), and tumour necrosis factor α (TNF- α) are associated with the incidence of Alzheimer's disease (AD), the most common form of dementia, accounting for 60-80% of all cases^{8,9}. However, longitudinal studies on the association between biomarkers of the inflammation-related proteome and dementia are scarce¹⁰.

As biomarkers can be measured at an early stage of dementia, they have the potential to be used for an early diagnosis^{11,12}. Furthermore, identified new biomarkers could deepen our understanding of the pathogenetic processes leading to dementia and might represent novel drug targets^{13,14}. The current challenge of biomarker research in dementia in general and distinct forms is to find reliable diagnostic and predictive biomarkers easily accessible in fluids like blood^{15,16}.

This study aims for the first time to identify blood-based biomarkers from a set of 92 inflammatory biomarkers as risk factors for all-cause dementia, Alzheimer's disease (AD), or vascular dementia (VD) incidence in a large, prospective cohort study with a 17-year follow-up.

2. Methods

2.1. Study population

We conducted a case-cohort study based on the ESTHER study (Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung [German]). In this prospective cohort study implemented in Saarland, Germany, 9,940 women and men aged 50 to 75 years at baseline were recruited during a general health checkup by their general practitioners between 2000 and 2002. Besides an age of 50-75 years, the inclusion criteria for the ESTHER study were physical and mental ability to participate in the study as well as knowledge of the German language. Participants were followed up concerning the incidence of major diseases and mortality 2, 5, 8, 11, 14, and 17 years after baseline. For details, see Löw et al. 2004¹⁷. The sociodemographic baseline characteristics and common prevalent chronic diseases were similarly distributed in the respective age categories as in the German National Health Survey, a representative sample of the German population¹⁷. The study was approved by the ethics committees of Heidelberg University and the state medical board of Saarland, Germany.

2.2. Dementia ascertainment

Information about a dementia diagnosis was collected during the 14- and 17-year-follow-ups of the ESTHER study. The median follow-up time was 16.3 years (interquartile-range: 13.5-17.0 years), and the maximum was 19.4 years due to the 2-year period of baseline recruitment. In brief, the collection of dementia diagnoses included sending standardized questionnaires to the study participants' general practitioners (GPs). Participants who had dropped out during previous follow-ups due to ill health or had died were included in the dementia ascertainment through the GPs as well. If the GPs were aware of a dementia diagnosis for their patients, they were asked to provide all available medical records documenting a dementia diagnosis. The latter included records from neurologists, psychiatrists, memory clinics, or other specialized providers. If the GP provided a mixed dementia diagnosis,

available medical records were screened for an underlying AD or VD background and considered as AD, VD, or both. The current guidelines in Germany for AD diagnosis follow the National Institute on Aging and the Alzheimer's Association¹⁸ or the International Working Group (IWG)-2 criteria^{19,20}.

2.3. Biomarker and covariate assessment

The serum of baseline blood samples was analyzed with the Olink Target 96 Inflammation panel, developed by Olink Proteomics (Uppsala, Sweden). The details for the biomarker and covariate assessment are shown in **Supplemental Text 1**.

2.4. In- and exclusion criteria

The selection of study participants from the ESTHER cohort for this case-cohort analysis is shown in **Supplemental Figure 1**. ESTHER participants were eligible for selection as cases or random controls. Participants were excluded if dementia incidence status could not be ascertained by GP questionnaires (n=3,583) or blood samples were not available (n=73). Thus, information from 6,284 participants was available for analyses. Olink inflammation panel measurements were performed in a case-cohort design among 1,435 randomly selected study participants and all incident dementia cases of the rest of the cohort (n=393). After excluding participants with quality control warning, 389 incident dementia cases and 1,393 randomly selected participants were available. As the random controls included 115 incident dementia cases, the study population comprised 504 participants with incident dementia and 1,278 randomly selected controls.

2.5. Statistical analyses

First, to describe factors associated with dementia risk, categorized baseline characteristics of all-cause dementia cases and controls were compared using the χ^2 -test. Second, odds ratios (ORs) were estimated with a multivariate logistic regression model, including all baseline characteristics.

In a univariate, descriptive analysis, the median and interquartile range (IQR) of all inflammation-related protein levels of all-cause dementia, AD, and VD cases were separately compared with those of controls, using the Wilcoxon Rank Sum test. Additionally, in a multivariate approach, the ORs per one standard deviation (SD) increase of each inflammation-related protein were assessed separately with each outcome (all-cause dementia, AD, and VD incidence) in logistic regression models adjusted for potential confounders. In models for AD incidence, study participants with other (e.g. VD) or unknown dementia forms were excluded. The same was applied for the outcome VD incidence by excluding AD and other non-VD cases. The models were adjusted for age, sex, education, physical activity, BMI, CVD, diabetes, depression, and *APOE* genotype. All variables were used as categorical variables, as described in Table 1, except age, which was modelled continuously. The covariates were selected because they were statistically significantly associated with all-cause dementia, AD, or VD in a previous analysis with the ESTHER study participants²¹. Statistical test results were corrected for multiple testing by the Benjamini and Hochberg method for all tests carried out for one outcome²². A false discovery rate (FDR) < 0.05 was applied as the threshold for statistical significance.

We further aimed to identify those inflammation-related proteins whose association with a dementia outcome was independent of other inflammatory biomarkers. Therefore, all biomarkers, which were significantly associated with a dementia endpoint after FDR correction, were tested for the independence of the association by forward elimination. In detail, only biomarkers having the strongest, independent, positive association with the outcome entered the regression model with the threshold for statistical significance of $p < 0.05$. The identified independent biomarkers were used for the naming of biomarker clusters. All other biomarkers of the Olink inflammation panel, which were highly correlated (Spearman's correlation coefficient $r > 0.5$)²³ with an independent biomarker, were put in its cluster. One biomarker might be in more than one cluster. We favoured this statistical approach over a principal component analysis (PCA) because it has a higher transparency, is easier to reproduce by others, its results are easier to interpret, and the associations of the biomarkers with the dementia outcomes are being acknowledged in the decision about the number of clusters.

The associations of the independent biomarkers with dementia endpoints were further analyzed in subgroup analyses based on age, sex, obesity, diabetes, history of CVD, and *APOE* ϵ 4 polymorphism. Apart from this, interaction terms were tested. In addition, the dose-response relationships between the independent biomarkers and dementia endpoints were assessed with restricted cubic spline curves²⁴. Information on sensitivity analyses and the imputation of missing covariate values are given in **Supplemental Text 2**.

3. Results

Table 1 shows the baseline characteristics of 504 cases with incident dementia from any cause and 1,278 controls. The χ^2 test revealed significant differences between cases and controls in terms of age, physical activity, cardiovascular disease (CVD), diabetes, lifetime history of depression, and *APOE* genotype. In the multivariate logistic regression analysis, CVD and diabetes lost statistical significance, but a trend towards an increased dementia risk could still be seen in the OR point estimates. Age, sex, lifetime history of depression with current pharmacotherapy and having at least one ϵ 4 allele of the *APOE* gene remained significantly positively associated with all-cause dementia incidence. In contrast, physical activity remained significantly inversely associated.

Among the included 504 all-cause dementia cases, 163 and 195 participants developed AD and VD, respectively. The medians of all inflammation-related protein levels of all-cause dementia, AD, and VD cases were separately compared with those of controls (**Supplemental Tables 2-4**). In this univariate analysis, $n = 60$, $n = 51$ and $n = 52$ biomarker levels of the Olink inflammation panel were significantly increased in all-cause dementia, AD, and VD cases, respectively (FDR < 0.05).

Tables 2-4 show the multivariate logistic regression model results for those 58, 22, and 33 biomarkers, significantly associated with all-cause dementia, AD, and VD incidence, respectively, after FDR correction. **Supplemental Tables 5-7** show the non-significant ones. The associations' strengths were

comparable and ranged for the various biomarker-outcome associations from OR point estimates of 1.12 to 1.51 per 1 SD increase. The forward selection revealed that only two (CX3CL1 and EN-RAGE), two (EN-RAGE and LAP TGF-beta-1), and one (VEGF-A) inflammation-related proteins were independently, positively associated with all-cause dementia, AD, and VD, respectively. The reason for the low number of independent inflammation biomarkers was mainly due to high inter-correlation. Overall, 18, 26, 16, and 28 biomarkers of the Olink inflammation panel had a Spearman's $r > 0.5$ with CX3CL1, EN-RAGE, LAP TGF-beta 1, and VEGF-A, respectively (**Supplemental Tables 8-11**).

When the two independent biomarkers for all-cause dementia were added simultaneously to the logistic regression models, the OR point estimates per 1 SD increase were attenuated but remained statistically significant (CX3CL1, OR [95% CI]: 1.29 [1.13-1.47], $p=0.0002$; EN-RAGE, OR [95% CI]: 1.31 [1.15-1.49], $p<0.0001$). This was also the case for the two independent biomarkers for AD (EN-RAGE, OR [95% CI]: 1.37 [1.10-1.68], $p=0.0048$; LAP TGF-beta-1, OR [95% CI]: 1.28 [1.04-1.58], $p=0.0187$). For VD, only one independent biomarker was included (VEGF-A, OR [95% CI]: 1.43 [1.20-1.70], $p<0.0001$). The dose-response curves of these five biomarker-dementia outcome associations are shown in **Figure 1**. The risk of VD seems to start to increase only at higher VEGF-A levels ($> 60^{\text{th}}$ percentile). The other four biomarker-dementia associations show a more or less linear risk increase over the whole biomarker level distribution.

The results for these five selected biomarker-dementia endpoint associations are shown stratified for age, sex, obesity, diabetes, CVD, *APOE* $\epsilon 4$ in **Supplemental Tables 12-16**. Generally, results were similar in subgroups defined by the first four factors. For *APOE* $\epsilon 4$, there was a consistent pattern towards stronger associations of inflammation biomarkers among *APOE* $\epsilon 4$ negative subjects. In line with this observation, the only statistically significant interaction found was between *APOE* $\epsilon 4$ polymorphism and the biomarker EN-RAGE for all-cause dementia ($p=0.024$, **Supplemental Table 13**).

The results of the sensitivity analyses are also shown in **Supplemental Tables 12-16**. When stratified by time of diagnosis, all selected biomarkers had a stronger association with dementia diagnoses

occurring in the first ten years of follow-up. However, significant associations were also observed for diagnoses in later years of follow-up. Besides, excluding subjects who died before their 80th birthday or had a sign of acute infection (CRP level >20mg/L) did not alter the results to any relevant extent.

4. Discussion

To our knowledge, this is the first prospective cohort study to analyze inflammation-related, blood-based biomarkers for all-cause dementia, AD, and VD incidence. We identified a high number of statistically significantly associated proteins with at least one of the outcomes, even after FDR correction. However, only a few biomarkers were strongly and independently associated with dementia outcomes because of a high inter-correlation between the biomarkers. The identified independent biomarkers include CX3CL1 (associated with all-cause dementia), EN-RAGE (associated with all-cause dementia and AD), LAP TGF-beta-1 (associated with AD), and VEGF-A (associated with VD). Each of these biomarkers is only one marker of an inflammatory protein cluster, in which the majority of biomarkers are associated with dementia.

4.1. Previous studies examining a set of inflammatory biomarkers

A few previous studies, mostly with a cross-sectional study design, investigated the association between single inflammatory biomarkers and all-cause dementia or AD⁶⁻⁹. To our knowledge, only one previous study examined a whole panel of inflammatory biomarkers for dementia as the outcome in a cross-sectional design. In the BioFINDER study, Whelan and colleagues measured 270 proteins with the Olink immunoassay in cerebrospinal fluid (CSF) and plasma of 161 AD patients, 75 amyloid beta positive (Aβ+) patients with mild cognitive impairment (MCI+), and 415 amyloid beta negative (Aβ-) cognitively normal individuals (MCI-)²⁵. Interestingly, approximately half of the CSF proteins correlated at least modestly with their analogues in plasma, indicating that findings in plasma samples partially reflected the situation in CSF. Compared to Aβ-/MCI- individuals, CSF levels of 32 proteins and plasma levels of 33 proteins were statistically significantly associated with AD (False discovery corrected p-

value < 0.05). The comparison of A β +/MCI+ patients with A β -/MCI- individuals, were replicated in an independent cohort. Thereby, 10 CSF and six plasma markers could be replicated. However, a replication analysis in an independent sample was not performed for AD. Six of the identified 33 proteins for AD in plasma samples corresponded with our findings in serum samples and can now be considered replicated by our study (Casp-8, CXCL5, CXCL6, ST1A1, TRAIL, uPA).

However, the study of Whelan and colleagues was cross-sectional and evidence from longitudinal studies on this field is still sparse¹⁰. The recently published longitudinal study of Walker et al. reported statistically significant associations between inflammatory biomarkers measured in midlife (C-reactive protein and a composite score of fibrinogen, white blood cell count, von Willebrand factor, and factor VIII) and cognitive decline over 20 years in a population-based cohort study with 12,336 participants²⁶. Our longitudinal results with a broad panel of inflammatory proteins and the endpoints all-cause dementia, AD and VD complement and expand these findings.

4.2. Independently associated biomarkers

The independently associated biomarkers CX3CL1, EN-RAGE, LAP TGF-beta-1 and VEGF-A likely play various important roles in the pathogenesis of dementia. While CX3CL1 is discussed to regulate microglial activation²⁷ and LAP TGF-beta-1 to be protective against A β deposition^{13,28}, VEGF-A is thought to increase the permeability of the blood brain barrier²⁹. EN-RAGE is less studied in the context of dementia³⁰. This was the first longitudinal cohort study, which reported an association of EN-RAGE with all-cause dementia and AD. More details about plausible mechanisms of these four biomarkers and other prominently discussed inflammatory proteins in the development of dementia are discussed in **Supplemental Text 3**. Furthermore, we discuss the *APOE* ϵ 4 specific results of our study there.

4.3. Strengths and limitations

The strengths of this study comprise a large sample size, the representative sample of an older adult population, a long follow-up period (17 years), and the prospective cohort design. Moreover, the

diversity of inflammatory biomarkers (72 biomarkers analyzed) and the high sensitivity and specificity of Olink's proximity extension assays^{31,32} used for the biomarker measurements can be assigned to the study's strengths.

The observational study design is one of the limitations of this study. Although analyses were controlled for confounders, residual confounding cannot be entirely excluded. Apart from this, the latency between the onset and the clinical diagnosis of dementia can be longer than the follow-up time of 17 years³³. However, results were still statistically significant after excluding events in the first ten years of follow-up. Thus, we can assume that there is no strong indication of reverse causality in our study results.

In the ESTHER study, dementia information is collected via GPs. After a referral to various neurologists, psychiatrists, memory clinics, or other specialized providers in the study region, diagnoses were obtained from the medical records of specialists. This process reflects the community-based clinical setting in Germany. Therefore, dementia diagnostics were performed heterogeneously, and dementia subtypes were often not assessed. This may be one reason why the ratio of AD to VD diagnoses is not as high in our study as in other studies with homogenous subtype diagnostics based on biomarkers of AD pathology among all study participants.

Due to cost issues, biomarker measurements were only performed for baseline blood samples and could not be repeated in follow-ups. Furthermore, findings could not be replicated in another independent study, which should be aimed at future research.

The biomarkers TNF and IFN-gamma had to be excluded since the proportion of values below LOD was > 25% in the total study sample. After Olink improved the inflammation panel in 2019, better results could be achieved for these biomarkers. However, the improved panel was only used in a fraction of our study sample (n = 440). When analyzing the data only in this sub-sample, TNF and IFN-gamma showed significant associations for all three analyzed dementia outcomes.

Lastly, it has to be stated that our study results refer to an almost exclusively Caucasian population with blood samples taken between the ages of 50 and 75 years and may not be generalized to other types of populations.

4.4. Conclusion

This study showed that 58 out of 72 tested proteins of the inflammatory proteome in blood were significantly associated with all-cause dementia incidence even after correction for multiple testing. Several inflammatory proteins were further associated with AD and VD. The biomarkers CX3CL1, EN-RAGE, LAP TGF-beta-1, and VEGF-A, had strong and independent associations with dementia outcomes and may have great potential as drug targets, early diagnostic markers, and components of dementia prediction scores. However, due to the observed high inter-correlation of inflammatory biomarkers, it should be noted that not only single biomarkers but also clusters of increased inflammatory protein levels may play a role in dementia pathogenesis or risk prediction. The complex interrelationships in these clusters are not yet understood and require further research.

References

1. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. *World Alzheimer Report 2015 - The Global Impact of Dementia an Analysis of Prevalence, Incidence, Cost, and Trends*. Alzheimer's Disease International; August 2015 2015.
2. Siva N. New global initiative to tackle Alzheimer's disease. *The Lancet*. 2021;397(10274):568-569.
3. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. *J Cereb Blood Flow Metab*. 2016;36(1):172-186.
4. Lim SL, Rodriguez-Ortiz CJ, Kitazawa M. Infection, systemic inflammation, and Alzheimer's disease. *Microbes and Infection*. 2015;17(8):549-556.
5. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y)*. 2018;4:575-590.
6. Darweesh SKL, Wolters FJ, Ikram MA, de Wolf F, Bos D, Hofman A. Inflammatory markers and the risk of dementia and Alzheimer's disease: A meta-analysis. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2018;14(11):1450-1459.
7. Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. *Journal of neurology, neurosurgery, and psychiatry*. 2017;88(10):876-882.
8. Su C, Zhao K, Xia H, Xu Y. Peripheral inflammatory biomarkers in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis. *Psychogeriatrics*. 2019;19(4):300-309.
9. Park J-C, Han S-H, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review. *BMB Rep*. 2020;53(1):10-19.
10. Walker KA. Inflammation and neurodegeneration: chronicity matters. *Aging*. 2018;11(1):3-4.
11. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2016;12(6):719-732.
12. McGeer PL, Rogers J, McGeer EG. Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years. *Journal of Alzheimer's disease : JAD*. 2016;54(3):853-857.
13. Shen L, Sijian X, Zhang H, et al. Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer's Disease. In: *Molecular Medicine*. IntechOpen; 2018.
14. Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. *Biomarkers in Neuropsychiatry*. 2019;1:100005.
15. Simrén J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. *Current opinion in neurobiology*. 2020;61:29-39.
16. Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer's disease. *Molecular Brain*. 2019;12(1):26.
17. Löw M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H. [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)]. *Deutsche medizinische Wochenschrift (1946)*. 2004;129(49):2643-2647.
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2011;7(3):263-269.
19. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. *The Lancet Neurology*. 2014;13(6):614-629.
20. *Neurologie DGf. S3-Leitlinie "Demenzen"*. Germany: Springer-Verlag GmbH; 2016.
21. Trares K, Gào X, Perna L, et al. Associations of urinary 8-iso-prostaglandin F(2α) levels with all-cause dementia, Alzheimer's disease, and vascular dementia incidence: results from a

- prospective cohort study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2020;16(5):804-813.
22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. 1995;57(1):289-300.
23. Spearman C. The Proof and Measurement of Association between Two Things. *The American Journal of Psychology*. 1904;15(1):72-101.
24. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. *Statistics in medicine*. 2010;29(9):1037-1057.
25. Whelan CD, Mattsson N, Nagle MW, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathol Commun*. 2019;7(1):169.
26. Walker KA, Gottesman RF, Wu A, et al. Systemic inflammation during midlife and cognitive change over 20 years. *The ARIC Study*. 2019;92(11):e1256-e1267.
27. Finneran DJ, Nash KR. Neuroinflammation and fractalkine signaling in Alzheimer's disease. *Journal of neuroinflammation*. 2019;16(1):30.
28. Estrada LD, Oliveira-Cruz L, Cabrera D. Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer's Disease. *Curr Protein Pept Sci*. 2018;19(12):1180-1188.
29. Kim J-H, Ko P-W, Lee H-W, et al. Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. *Glia*. 2017;65(9):1471-1490.
30. Cristóvão JS, Gomes CM. S100 Proteins in Alzheimer's Disease. *Frontiers in Neuroscience*. 2019;13(463).
31. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PloS one*. 2014;9(4):e95192.
32. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic acids research*. 2011;39(15):e102.
33. Ritchie K, Carrière I, Berr C, et al. The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories. *J Clin Psychiatry*. 2016;77(3):e305-311.

Acknowledgements

The authors have no conflicts of interest to disclose. Financial support for research staff involved in this project was granted by the Baden-Württemberg State Ministry of Science, Research and Arts (Stuttgart, Germany), the Robert-Bosch-Stiftung (Stuttgart, Germany) and the Klaus-Tschira-Stiftung gGmbH (Heidelberg, Germany). The ESTHER study was funded by grants from the Baden-Württemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany), the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany), and the Saarland state ministry for Social Affairs, Health, Women and Family Affairs (Saarbrücken, Germany).

Tables

Table 1. Baseline characteristics of included study participants (n=1782)

Baseline characteristics	n (%)	All-cause dementia cases (n=504)	Controls (n=1278)	χ^2 test p-value	Multivariate Odds Ratio (95%CI) ^c
Age (years)				< 0.0001	
50-64	956 (53.65)	154 (30.56)	802 (62.75)		1.00 Ref.
65-69	458 (25.70)	157 (31.15)	301 (23.55)		2.57 (1.96-3.37)
70-75	368 (20.65)	193 (38.29)	175 (13.69)		5.37 (4.03-7.15)
Sex				0.2486	
Female	965 (54.15)	262 (51.98)	703 (55.01)		1.00 Ref.
Male	817 (45.85)	242 (48.02)	575 (44.99)		1.28 (1.01-1.63)
Education (years)				0.0868	
< 9	1344 (77.42)	391 (80.79)	953 (76.12)		1.00 Ref.
9-11	216 (12.44)	48 (9.92)	168 (13.42)		0.84 (0.58-1.23)
≥ 12	176 (10.14)	45 (9.30)	131 (10.46)		0.93 (0.62-1.38)
Physical activity^a				< 0.0001	
Inactive	383 (21.54)	150 (29.82)	233 (18.27)		1.00 Ref.
Low	814 (45.78)	220 (43.74)	594 (46.59)		0.65 (0.49-0.86)
Medium or high	581 (32.68)	133 (26.44)	448 (35.14)		0.60 (0.44-0.83)
BMI (kg/m²)				0.5708	
< 25	478 (26.91)	144 (28.63)	334 (26.24)		1.00 Ref.
25-<30	832 (46.85)	228 (45.33)	604 (47.45)		0.85 (0.65-1.12)
≥30	466 (26.24)	131 (26.04)	335 (26.32)		0.85 (0.62-1.17)
CVD^b				< 0.0001	
No	1373 (77.05)	350 (69.44)	1023 (80.05)		1.00 Ref.
Yes	409 (22.95)	154 (30.56)	255 (19.95)		1.20 (0.92-1.56)
Diabetes				0.0001	
No	1469 (83.61)	386 (78.14)	1083 (85.75)		1.00 Ref.
Yes	288 (16.39)	108 (21.86)	180 (14.25)		1.29 (0.96-1.74)
Life-time history of depression				0.0225	
No	1527 (85.69)	427 (84.72)	1100 (86.07)		1.00 Ref.
Yes, without current pharmacotherapy	184 (10.33)	47 (9.33)	137 (10.72)		1.01 (0.69-1.49)
Yes, with current pharmacotherapy	71 (3.98)	30 (5.95)	41 (3.21)		2.26 (1.33-3.85)
APOE genotypes				< 0.0001	
ε2/ε2	18 (1.09)	1 (0.22)	17 (1.42)		0.25 (0.04-1.47)
ε2/ε3	238 (14.43)	57 (12.58)	181 (15.13)		1.06 (0.75-1.52)
ε2/ε4	55 (3.34)	22 (4.86)	33 (2.76)		2.77 (1.52-5.06)
ε3/ε3	929 (56.34)	218 (48.12)	711 (59.45)		1.00 Ref.
ε3/ε4	379 (22.98)	135 (29.80)	244 (20.40)		1.79 (1.35-2.37)
ε4/ε4	30 (1.82)	20 (4.42)	10 (0.84)		7.15 (3.18-16.08)

Abbreviations: CI, confidence interval; BMI, body mass index; CVD, cardiovascular disease; *APOE*, apolipoprotein E;

NOTE: Numbers printed in bold are statistically significant ($p < 0.05$).

^a “Inactive” was defined by < 1 h of vigorous or < 1 h light physical activity per week. “Medium or high” was defined by ≥ 2 h of vigorous and ≥ 2 h of light physical activity/week. All other amounts of physical activity were grouped into the category “Low”.

^b CVD was defined as coronary artery disease or a self-reported history of myocardial infarction, stroke, pulmonary embolism, or revascularization of coronary arteries.

^c Results of multivariate logistic regression model including all variables shown in this table (imputed dataset).

Table 2. Associations of significantly associated Olink Biomarker levels with **all-cause dementia** incidence.

Olink Biomarker	Value of 1 SD	All-cause dementia (n=504 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
ADA	0.635	1.17 (1.05-1.32)	0.0055	0.0098
AXIN1	1.140	1.14 (1.02-1.28)	0.0257	0.0352
CASP-8	1.364	1.15 (1.02-1.29)	0.0194	0.0279
CCL3	1.508	1.14 (1.02-1.27)	0.0259	0.0352
CCL4	1.099	1.19 (1.06-1.33)	0.0032	0.0066
CCL11	0.697	1.29 (1.14-1.46)	0.0001	0.0003
CCL19	1.199	1.17 (1.05-1.32)	0.0063	0.0108
CCL20	1.540	1.18 (1.05-1.32)	0.0041	0.0082
CCL23	0.732	1.29 (1.14-1.46)	<0.0001	0.0003
CCL25	0.763	1.17 (1.03-1.32)	0.0122	0.0187
CCL28	0.548	1.27 (1.13-1.43)	<0.0001	0.0003
CD5	0.523	1.26 (1.12-1.42)	0.0002	0.0007
CD6	0.757	1.19 (1.05-1.34)	0.0048	0.0093
CD40	0.734	1.20 (1.07-1.36)	0.0022	0.0050
CD244	0.587	1.38 (1.22-1.57)	<0.0001	0.0003
CDCP1	0.894	1.20 (1.06-1.36)	0.0030	0.0064
CSF-1	0.425	1.24 (1.09-1.41)	0.0013	0.0032
CST5	0.698	1.17 (1.04-1.32)	0.0112	0.0179
CX3CL1	0.669	1.41 (1.24-1.60)	<0.0001	0.0003
CXCL1	0.901	1.17 (1.05-1.32)	0.0065	0.0109
CXCL5	0.957	1.33 (1.17-1.51)	<0.0001	0.0003
CXCL6	0.848	1.28 (1.14-1.44)	0.0001	0.0003
CXCL9	0.953	1.19 (1.05-1.34)	0.0052	0.0096
CXCL10	0.953	1.16 (1.03-1.30)	0.0138	0.0207
CXCL11	1.051	1.18 (1.05-1.33)	0.0051	0.0096
DNER	0.488	1.36 (1.20-1.55)	<0.0001	0.0003
EN-RAGE	1.307	1.41 (1.25-1.60)	<0.0001	0.0003
FGF-19	1.089	1.21 (1.08-1.35)	0.0013	0.0032
Flt3L	0.629	1.21 (1.07-1.36)	0.0018	0.0042
GDNF	0.506	1.16 (1.03-1.30)	0.0149	0.0219
HGF	0.719	1.34 (1.18-1.52)	<0.0001	0.0003
IL-7	0.798	1.14 (1.02-1.28)	0.0246	0.0347
IL-10	0.863	1.20 (1.07-1.35)	0.0023	0.0050
IL-18	0.763	1.33 (1.17-1.50)	<0.0001	0.0003
IL-10RA	0.788	1.12 (1.01-1.25)	0.0362	0.0461
IL-10RB	0.533	1.29 (1.14-1.46)	0.0001	0.0003
IL-15RA	0.359	1.22 (1.09-1.38)	0.0009	0.0026
IL-18R1	0.602	1.27 (1.13-1.44)	0.0001	0.0003
LAP TGF-beta-1	0.574	1.37 (1.21-1.55)	<0.0001	0.0003
LIF-R	0.503	1.37 (1.21-1.56)	<0.0001	0.0003
MCP-2	0.769	1.18 (1.05-1.33)	0.0069	0.0113
MCP-4	0.927	1.23 (1.08-1.39)	0.0015	0.0036
MMP-10	0.761	1.22 (1.08-1.37)	0.0010	0.0028
NT-3	0.544	1.24 (1.10-1.39)	0.0003	0.0009
OPG	0.609	1.39 (1.22-1.58)	<0.0001	0.0003
PD-L1	0.600	1.30 (1.15-1.47)	<0.0001	0.0003
SCF	0.624	1.15 (1.01-1.29)	0.0281	0.0375
SIRT2	1.157	1.13 (1.01-1.27)	0.0371	0.0461
ST1A1	1.304	1.13 (1.01-1.27)	0.0365	0.0461
STAMBP	0.833	1.18 (1.05-1.32)	0.0056	0.0098

TGF- α	0.829	1.21 (1.08-1.37)	0.0011	0.0029
TNFRSF9	0.636	1.23 (1.09-1.39)	0.0006	0.0018
TNFSF14	1.064	1.16 (1.03-1.30)	0.0119	0.0186
TRAIL	0.513	1.31 (1.16-1.49)	<0.0001	0.0003
TRANCE	0.753	1.14 (1.01-1.28)	0.0344	0.0450
TWEAK	0.647	1.35 (1.19-1.53)	<0.0001	0.0003
VEGF-A	0.794	1.40 (1.24-1.59)	<0.0001	0.0003
uPA	0.604	1.36 (1.20-1.54)	<0.0001	0.0003

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

Notes: Numbers printed in bold are statistically significant ($p < 0.05$). Grey shade: Independently associated with the outcome. For associations of not significantly associated biomarkers, see Supplemental Table 5.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Table 3. Associations of significantly associated Olink Biomarker levels with **Alzheimer's disease** incidence.

Olink Biomarker	Value of 1 SD	Alzheimer's disease (n=163 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
CASP-8	1.364	1.31 (1.10-1.57)	0.0025	0.0156
CCL23	0.732	1.43 (1.17-1.75)	0.0004	0.0086
CCL28	0.548	1.36 (1.14-1.61)	0.0005	0.0086
CD6	0.757	1.30 (1.08-1.58)	0.0067	0.0254
CD244	0.587	1.39 (1.14-1.70)	0.0010	0.0120
CX3CL1	0.669	1.35 (1.10-1.65)	0.0034	0.0175
CXCL5	0.957	1.37 (1.12-1.68)	0.0023	0.0156
CXCL6	0.848	1.34 (1.11-1.62)	0.0026	0.0156
DNER	0.488	1.37 (1.12-1.68)	0.0025	0.0156
EN-RAGE	1.307	1.51 (1.25-1.83)	<0.0001	0.0036
HGF	0.719	1.36 (1.12-1.66)	0.0017	0.0153
IL-10RB	0.533	1.33 (1.08-1.63)	0.0066	0.0254
LAP TGF-beta-1	0.574	1.46 (1.21-1.76)	0.0001	0.0036
LIF-R	0.503	1.31 (1.08-1.60)	0.0062	0.0254
PD-L1	0.600	1.31 (1.09-1.57)	0.0034	0.0175
ST1A1	1.304	1.30 (1.08-1.57)	0.0062	0.0254
STAMBP	0.833	1.26 (1.06-1.51)	0.0108	0.0370
TGF-alpha	0.829	1.26 (1.05-1.52)	0.0140	0.0458
TRAIL	0.513	1.30 (1.06-1.59)	0.0104	0.0370
TWEAK	0.647	1.38 (1.13-1.69)	0.0016	0.0153
VEGF-A	0.794	1.32 (1.09-1.60)	0.0042	0.0202
uPA	0.604	1.40 (1.16-1.71)	0.0006	0.0086

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

Notes: Numbers printed in bold are statistically significant ($p < 0.05$). Grey shade: Independently associated with the outcome. For associations of not significantly associated biomarkers, see Supplemental Table 6.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Table 4. Associations of significantly associated Olink Biomarker levels with **vascular dementia** incidence.

Olink Biomarker	Value of 1 SD	Vascular dementia (n=195 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
CCL11	0.697	1.30 (1.09-1.56)	0.0042	0.0137
CCL23	0.732	1.24 (1.04-1.48)	0.0148	0.0347
CD5	0.523	1.32 (1.11-1.56)	0.0016	0.0091
CD244	0.587	1.39 (1.16-1.66)	0.0004	0.0072
CDCP1	0.894	1.25 (1.05-1.48)	0.0122	0.0313
CX3CL1	0.669	1.35 (1.13-1.61)	0.0011	0.0072
CXCL1	0.901	1.22 (1.04-1.43)	0.0151	0.0347
CXCL5	0.957	1.39 (1.16-1.67)	0.0004	0.0072
CXCL6	0.848	1.32 (1.11-1.57)	0.0018	0.0091
CXCL9	0.953	1.25 (1.06-1.47)	0.0089	0.0256
CXCL10	0.953	1.28 (1.09-1.50)	0.0029	0.0116
DNER	0.488	1.37 (1.13-1.65)	0.0010	0.0072
EN-RAGE	1.307	1.41 (1.18-1.68)	0.0001	0.0036
Fit3L	0.629	1.22 (1.03-1.45)	0.0226	0.0493
HGF	0.719	1.32 (1.11-1.58)	0.0019	0.0091
IL-7	0.798	1.24 (1.05-1.47)	0.0107	0.0296
IL-10	0.863	1.27 (1.09-1.48)	0.0017	0.0091
IL-18	0.763	1.36 (1.14-1.63)	0.0006	0.0072
IL-18R1	0.602	1.30 (1.09-1.55)	0.0034	0.0122
LAP TGF-beta-1	0.574	1.33 (1.12-1.57)	0.0011	0.0072
LIF-R	0.503	1.36 (1.14-1.63)	0.0007	0.0072
MCP-2	0.769	1.24 (1.04-1.47)	0.0154	0.0347
MCP-4	0.927	1.26 (1.05-1.51)	0.0114	0.0304
MMP-10	0.761	1.30 (1.10-1.54)	0.0022	0.0099
NT-3	0.544	1.26 (1.08-1.46)	0.0025	0.0106
OPG	0.609	1.38 (1.15-1.67)	0.0007	0.0072
PD-L1	0.600	1.26 (1.07-1.49)	0.0056	0.0175
TGF-alpha	0.829	1.23 (1.05-1.46)	0.0126	0.0313
TNFRSF9	0.636	1.26 (1.06-1.49)	0.0073	0.0219
TRAIL	0.513	1.32 (1.09-1.59)	0.0037	0.0127
TWEAK	0.647	1.36 (1.13-1.63)	0.0010	0.0072
VEGF-A	0.794	1.43 (1.20-1.70)	0.0001	0.0036
uPA	0.604	1.30 (1.09-1.55)	0.0034	0.0122

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

Notes: Numbers printed in bold are statistically significant ($p < 0.05$). Grey shad: Independently associated with the outcome. For associations of not significantly associated biomarkers, see Supplemental Table 7.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Figure 1. Association of all-cause dementia with (A) CX3CL1 and (B) EN-RAGE, Alzheimer's disease with (C) EN-RAGE and (D) LAP TGF-beta-1, and vascular dementia with (E) VEGFA in a spline regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), cardiovascular disease, diabetes, depression, APOE genotype.

Solid lines: estimation; dashed curved lines: 95% confidence interval limits; dashed horizontal line: reference line (hazard ratio = 1); dots: knots (20th, 40th, 60th, and 80th percentile).

Abbreviations: NPX, Normalized Protein eXpression

Supplemental Material to Article

“Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study”

Table of Contents

Supplemental Text 1.....	2
Supplemental Text 2.....	4
Supplemental Text 3.....	5
Supplemental Figure 1.....	9
Supplemental Table 1.....	10
Supplemental Table 2.....	13
Supplemental Table 3.....	15
Supplemental Table 4.....	17
Supplemental Table 5.....	19
Supplemental Table 6.....	20
Supplemental Table 7.....	22
Supplemental Table 8.....	23
Supplemental Table 9.....	24
Supplemental Table 10.....	25
Supplemental Table 11.....	26
Supplemental Table 12.....	27
Supplemental Table 13.....	28
Supplemental Table 14.....	29
Supplemental Table 15.....	30
Supplemental Table 16.....	31
References.....	32

Supplemental Text 1

Biomarker assessment

Inflammation-related, blood-based proteins were measured from serum samples collected during the health checkup at baseline (2000-2002). Blood samples were sent to the study centre and stored at -80°C until biomarker measurements took place in March 2018, December 2018, and September 2020 (referred to as time points t1, t2 and t3 in the following). At the time of the measurements, 10-25 µl of serum was extracted from different aliquots that have been thawed twice and sent with dry ice to the laboratories, which analyzed the samples with the Olink Target 96 Inflammation panel, Olink Proteomics, Uppsala, Sweden. At t1 and t2, samples were analyzed in the laboratory of Olink Proteomics, Uppsala Science Park, SE-75183 Uppsala, Sweden. At t3, the measurements were performed in the Research Unit Protein Science, German Research Center for Environmental Health, Helmholtz Center Munich, Heidemannstraße 1, 80939 München, Germany.

The Olink panels are based on a Proximity Extension Assay technology (PEA)^{1,2}. Details on the reliability and stability of the technology are described elsewhere³. In brief, oligonucleotide labelled antibody probe pairs are allowed to bind to their respective target proteins in the samples. Only if two antibodies are in close proximity, a polymerase chain reaction (PCR) reporter sequence is formed by DNA polymerization. This sequence is detected and quantified using high throughput real-time quantitative PCR (qPCR) (Fluidigm® Biomark™ HD system). The Olink Target 96 Inflammation panel allows the measurement of 92 biomarkers per sample. A list of all biomarkers of this panel is displayed in **Supplemental Table 1**.

At t1, t2 and t3, 22, 15 and 5 plates were used, respectively. To avoid batch effects, cases and controls were randomly distributed across plates and adjusted according to included interpolate controls. The average intra-assay coefficient of variance among all 92 measured biomarkers was 7%, 4% and 3% at t1, t2 and t3, respectively. The average inter-assay coefficient of variance was 12%, 10% and 10% at t1, t2 and t3, respectively. Furthermore, the quality of each serum samples was assessed by Olink technology. All samples were measured successfully, and the number of quality control warnings was

below 4% in all three timepoints. Of the 1,435 randomly selected controls and 393 incident dementia cases, 46 serum samples of participants were excluded due to a quality control warning by Olink.

Protein levels are reported as Normalized Protein eXpression (NPX) values, a relative quantification unit logarithmically related to protein concentration. The number of samples with values below the lower limit of detection (LOD) varied strongly by biomarker and is shown in Supplemental Table 1 (Appendix). In total, 20 biomarkers with > 25 % of the values below LOD were excluded from all analyses (grey shaded biomarkers in Supplemental Table 1). Thereby, 72 out of the 92 biomarkers were considered evaluable markers. Biomarker values below the LOD were replaced by LOD/ $\sqrt{2}$. The normalization of raw data was conducted with the R (R Core Team, 2020, version 3.6.3) package “OlinkAnalyze”, developed and maintained by the Olink Proteomics Data Science Team⁴. For this procedure, bridging samples were used to normalize data from three different measurement time points.

Covariate assessment

Data on sex, age, education, body mass index (BMI), physical activity, and lifetime history of depression were collected during baseline assessment through a standardized self-administered questionnaire. The history of coronary heart disease (CHD) and diabetes mellitus were obtained from physician diagnoses. Furthermore, anti-diabetic drugs reported by the GP were used to complement diabetes mellitus diagnoses. Participants were considered to have cardiovascular disease (CVD) based upon CHD diagnoses from GPs or self-reported history of myocardial infarction, stroke, pulmonary embolism, or revascularization of coronary arteries. TaqMan single-nucleotide polymorphism (SNP) genotyping assays were used to determine Apolipoprotein E (*APOE*) genotypes. More precisely, genotypes were analyzed in an endpoint allelic discrimination using a PRISM 7000 Sequence detection system (Applied Biosystems)⁵.

Supplemental Text 2

Sensitivity analyses

Several sensitivity analyses were performed. To check for potential reverse causality, the associations between the independent biomarkers and dementia endpoints were analyzed stratified by time of diagnosis (in the first ten years of follow-up vs later years). Competing risk of death was examined by excluding subjects without dementia diagnosis who died before their 80th birthday, the average life expectancy of the cohort's population. Fractional polynomials with first-order terms were used to determine each biomarker's best fitting function with the outcomes⁶. Since the linear function was the best fitting one for almost all biomarkers (68 of 72), all were modelled linearly. Finally, to examine the impact of persons with a potential acute infection on the overall results, subjects with C-reactive protein (CRP) levels > 20 mg/L were excluded.

Imputation of missing covariate values

To our knowledge, missing values of covariates were missing at random. The highest proportion of missing values was found for *APOE* polymorphism (7.7%). Thus, multiple imputation was used to impute missing values. Variables shown in Table 1 were used for the imputation model. Twenty data sets were imputed with the Markov Chain Monte Carlo (MCMC) method separately by sex with the SAS procedure PROC MI. All analyses were performed based on those 20 datasets with the SAS procedure PROC MIANALYZE.

Statistical tests were two-sided using an alpha level of 0.05. All statistical analyses were conducted with the Statistical Analysis System (SAS, version 9.4, Cary, North Carolina, USA).

Supplemental Text 3.

Previous studies and pathways to dementia of selected biomarkers with independent associations

CX3CL1

The biomarker CX3CL1, which is also commonly known as Fractalkine in humans, was independently associated with all-cause dementia and among the list of statistically significant biomarkers for AD and VD in our study. This biomarker is a chemokine binding to its receptor C-X3-C motif chemokine receptor 1 (CX3CR1) in a one-to-one relationship. While CX3CL1 is usually expressed in neurons, CX3CR1 is expressed on microglia. In the case of neuroinflammation, CX3CL1 regulates microglial activation by reducing the release of pro-inflammatory products⁷. Whether the effect of CX3CL1 is neuroprotective or neurotoxic in diseases like dementia is still controversially discussed in the literature. The current opinion is that this depends on the disease state, the affected CNS area, and the local concentration of the CX3CL1/CX3CR1 complex^{7,8}.

Nevertheless, due to the regulatory function in inflammation, this biomarker is a promising therapeutic target. A recent Polish study reported on the predictive ability of CX3CL1 as a biomarker in the early development of mild cognitive impairment (MCI) and AD⁹. In this study, significantly higher CSF and blood levels of CX3CL1 were found in MCI and AD patients compared to cognitively healthy controls. We now confirm these results with longitudinal data, including 17 years of follow-up.

EN-RAGE

EN-RAGE was independently associated with all-cause dementia and AD. In addition, EN-RAGE was significantly associated with VD. EN-RAGE is also often referenced as S100-A12. The S100-protein family has already been shown multiple times to be related to AD¹⁰. However, the S100-A12 protein (EN-RAGE) is the least studied S100 protein in the context of AD and dementia¹⁰. In the only available study, Shepherd and colleagues revealed associations of EN-RAGE with senile plaques, reactive glia,

and neurons in brain samples of sporadic and familial (PS-1) AD cases in a cross-sectional study¹¹. Our study is the first longitudinal cohort study reporting on this association.

EN-RAGE is a calcium-, zinc-, and copper-binding protein. In previous studies, it was shown to be associated with diseases like heart failure¹² and coronary artery disease (CAD) in diabetes patients¹³. Recently, Feng and colleagues reported significantly elevated EN-RAGE concentrations in patients with traumatic brain injury compared to controls¹⁴. In this study, EN-RAGE showed great potential as a marker for ongoing inflammatory processes in the brain. RAGE, the receptor EN-RAGE binds to, is additionally known to be involved in inflammatory processes related to ageing and neurodegeneration^{15,16}.

LAP-TGF-beta-1

LAP TGF-beta-1 is an anti-inflammatory cytokine that was independently associated with AD in our study (OR [95% CI]: 1.46 [1.21-1.76]). Additionally, it was significantly associated with all-cause dementia and VD. This biomarker consists of two components, latency-associated peptide (LAP) and transforming growth factor beta-1 (TGF-beta-1), which are non-covalently linked to each other in the intracellular environment. Thereby, LAP keeps TGF-beta-1 biologically inactive¹⁷. When activated, TGF-beta-1 binds to its receptor transforming growth factor- β receptor type I (T β R-1), protecting neurons against A β deposits and apoptosis^{18,19}. However, controversial findings have been reported on concentrations of this biomarker in AD²⁰. The current theory is that the level of TGF-beta-1 in the body might depend on disease progression²⁰. According to this theory, the reported elevated levels of TGF-beta-1 in our study might show an early response to commencing neurodegenerative processes in AD. A recent study additionally reported on the specificity of TGF-beta-1 for AD and VD compared to Parkinson's disease dementia (PDD)²¹.

VEGF-A

In our cohort, VEGF-A was independently associated with VD (OR [95% CI]: 1.43 [1.20-1.70]) and also significantly associated with all-cause dementia and AD. VEGF-A belongs to the vascular endothelial growth factor (VEGF) family and induces endothelial cell growth, cell migration, and permeabilization of blood vessels. Like other members of this family, VEGF-A induces the receptors VEGF receptor 1 and 2 (VEGFR-1 and VEGFR-2)²². In VD, VEGF-A is reported to be involved in microvessel loss and blood-brain barrier breakdown²³. It was shown in the same study in mice that VEGF-A is involved in the hypoxia-inducible factor 1 α -Lipocalin2-VEGFA (HIF-1 α -LCN2-VEGFA) axis. Other groups have also shown an involvement of VEGF-A in increasing blood-brain barrier permeability^{24,25}. Hence, blocking VEGF-A signalling might be a promising therapeutic target²⁶.

Inflammatory proteins prominently discussed in dementia research and biomarker clusters

Interestingly, the frequently discussed inflammatory biomarker IL-6 was not significantly associated with any dementia outcome in our study but highly correlated with EN-RAGE and VEGF-A [6-8]. However, apart from the inflammatory biomarkers discussed above, many others were statistically significantly associated with dementia outcomes as well but highly correlated with the highlighted proteins. IL-10, for example, is currently discussed by others as a risk factor for AD²⁷. In our study, IL-10 was also statistically significantly associated with all-cause dementia and VD even after correction for multiple testing. In addition, a subunit of the IL-10 receptor (IL-10RB) was significantly associated with all-cause dementia and AD. Both IL-10 and IL-10RB were highly correlated with VEGF-A and IL-10RB, additionally with LAP TGF-beta-1 and CX3CL1. Due to the high correlation of these biomarkers, it is not possible to decide with our study design which of the biomarkers are the most clinically relevant ones and are causally associated with the outcome. Basic research is needed to elucidate this open question and the role of the identified biomarkers in the etiology of dementia. The underlying mechanisms are likely to be complex because it is known that the multifactorial process of inflammation comes along with increases in the levels of many inflammatory proteins. Therefore, it

might be necessary to look into inflammatory protein networks/clusters rather than focusing on single proteins in future studies. For example, for AD, we identified two such protein clusters. The EN-RAGE and the LAP TGF-beta-1 cluster consist of respectively nine inflammatory proteins significantly associated with AD (**Supplemental Tables 9 and 10**). The overlap of the two clusters is only three proteins (HGF, CD244 and uPA).

Role of *APOE* ϵ 4 polymorphism

APOE ϵ 4 negative subjects had stronger associations between inflammation biomarkers and dementia outcomes than *APOE* ϵ 4 positive individuals. Interestingly, the interaction of *APOE* ϵ 4 and EN-RAGE for all-cause dementia was statistically significant. One explanation could be that the absolute AD risk of *APOE* ϵ 4 carriers is so pronounced that the additional presence or absence of a weaker risk factor, such as inflammation, may not have much impact. In contrast, the potential impact of inflammation on the total dementia risk of *APOE* ϵ 4 non-carriers is relatively high compared to other dementia risk factors.

Supplemental Figure 1. Flowchart of dementia ascertainment during the 14- and 17-year follow-up of the ESTHER study and selection of the study population for this research project.

Abbreviations: GP, general practitioner.

Supplemental Table 1. List of biomarkers measured with Olink Proseek® Multiplex Inflammation I^{96x96} kits.

Abbreviation	Biomarker name	Values < LOD
4E-BP1	Eukaryotic translation initiation factor 4E-binding protein 1	0%
ADA	Adenosine Deaminase	0%
ARTN	Artemin	76%
AXIN1	Axin-1	5%
Beta-NGF	Beta-nerve growth factor	12%
CASP-8	Caspase-8	0%
CCL11	Eotaxin	0%
CCL19	C-C motif chemokine 19	0%
CCL20	C-C motif chemokine 20	0%
CCL23	C-C motif chemokine 23	0%
CCL25	C-C motif chemokine 25	0%
CCL28	C-C motif chemokine 28	2%
CCL3	C-C motif chemokine 3	0%
CCL4	C-C motif chemokine 4	0%
CD244	Natural killer cell receptor 2B4	0%
CD40	CD40L receptor	0%
CD5	T-cell surface glycoprotein CD5	0%
CD6	T cell surface glycoprotein CD6 isoform	0%
CD8A	T-cell surface glycoprotein CD8 alpha chain	0%
CDCP1	CUB domain-containing protein 1	0%
CSF-1	Macrophage colony-stimulating factor 1	0%
CST5	Cystatin D	3%
CX3CL1	Fractalkine	0%
CXCL1	C-X-C motif chemokine 1	0%
CXCL10	C-X-C motif chemokine 10	0%
CXCL11	C-X-C motif chemokine 11	0%
CXCL5	C-X-C motif chemokine 5	0%
CXCL6	C-X-C motif chemokine 6	0%
CXCL9	C-X-C motif chemokine 9	0%
DNER	Delta and Notch-like epidermal growth factor-related receptor	0%
EN-RAGE	Protein S100-A12	0%
FGF-19	Fibroblast growth factor 19	0%
FGF-21	Fibroblast growth factor 21	0%
FGF-23	Fibroblast growth factor 23	25%
FGF-5	Fibroblast growth factor 5	40%
Flt3L	Fms-related tyrosine kinase 3 ligand	0%
GDNF	Glial cell line-derived neurotrophic factor	25%
HGF	Hepatocyte growth factor	0%
IFN_gamma	Interferon gamma	81%
IL1_alpha	Interleukin-1 alpha	85%
IL-10	Interleukin-10	3%
IL-10RA	Interleukin-10 receptor subunit alpha	22%
IL-10RB	Interleukin-10 receptor subunit beta	0%
IL-12B	Interleukin-12 subunit beta	0%
IL13	Interleukin-13	86%

Abbreviation	Biomarker name	Values < LOD
IL-15RA	Interleukin-15 receptor subunit alpha	20%
IL-17A	Interleukin-17A	28%
IL-17C	Interleukin-17C	32%
IL-18	Interleukin-18	0%
IL-18R1	Interleukin-18 receptor 1	0%
IL2	Interleukin-2	98%
IL20	Interleukin-20	78%
IL-20RA	Interleukin-20 receptor subunit alpha	47%
IL22-RA1	Interleukin-22 receptor subunit alpha-1	83%
IL24	Interleukin-24	90%
IL2RB	Interleukin-2 receptor subunit beta	66%
IL33	Interleukin-33	97%
IL4	Interleukin-4	85%
IL-5	Interleukin-5	62%
IL-6	Interleukin-6	1%
IL-7	Interleukin-7	0%
IL-8	Interleukin-8	0%
LAP TGF-beta-1	Latency-associated peptide transforming growth factor beta-1	0%
LIF	Leukemia inhibitory factor	65%
LIFR	Leukemia inhibitory factor receptor	0%
MCP-1	Monocyte chemotactic protein 1	0%
MCP-2	Monocyte chemotactic protein 2	0%
MCP-3	Monocyte chemotactic protein 3	5%
MCP-4	Monocyte chemotactic protein 4	0%
MMP-1	Matrix metalloproteinase-1	0%
MMP-10	Matrix metalloproteinase-10	0%
NRTN	Neurturin	72%
NT-3	Neurotrophin-3	13%
OPG	Osteoprotegerin	0%
OSM	Oncostatin-M	0%
PD-L1	Programmed cell death 1 ligand 1	0%
SCF	Stem cell factor	0%
SIRT2	SIR2-like protein 2	7%
SLAMF1	Signaling lymphocytic activation molecule	9%
ST1A1	Sulfotransferase 1A1	4%
STAMBP	STAM-binding protein	0%
TGF-alpha	Transforming growth factor alpha	0%
TNF	Tumor necrosis factor	70%
TNFB	TNF-beta	0%
TNFRSF9	Tumor necrosis factor receptor superfamily member 9	0%
TNFSF14	Tumor necrosis factor ligand superfamily member 14	0%
TRAIL	TNF-related apoptosis-inducing ligand	0%
TRANCE	TNF-related activation-induced cytokine	0%
TSLP	Thymic stromal lymphopoietin	87%
TWEAK	Tumor necrosis factor (Ligand) superfamily, member 12	0%
uPA	Urokinase-type plasminogen activator	0%
VEGF-A	Vascular endothelial growth factor-A	0%

Note: Grey shade indicates biomarkers with 25% or more of the values below the lower limit of detection (LOD)

Supplemental Table 2. Comparison of median biomarker levels between all-cause dementia cases (n=504) and controls (n=1278)

Olink Biomarker	All-cause dementia cases (n=504) Median (IQR)	Controls (n=1278) Median (IQR)	p-value ^a	FDR ^b
ADA	6.47 (6.09-6.82)	6.38 (6.02-6.73)	0.0041	0.0029
AXIN1	3.72 (2.61-4.35)	3.60 (2.49-4.26)	0.0662	0.0536
Beta-NGF	0.61 (0.60-0.67)	0.61 (0.43-0.77)	0.3080	0.2807
CASP-8	6.09 (5.15-7.09)	5.93 (5.02-6.85)	0.0248	0.0197
CCL3	7.25 (6.65-8.00)	7.03 (6.49-7.77)	<0.0001	<0.0001
CCL4	7.41 (6.87-8.10)	7.25 (6.71-7.87)	0.0006	0.0004
CCL11	8.67 (8.27-9.06)	8.54 (8.15-8.89)	<0.0001	<0.0001
CCL19	9.12 (8.49-9.84)	8.84 (8.31-9.54)	<0.0001	<0.0001
CCL20	6.74 (6.04-7.57)	6.44 (5.76-7.27)	<0.0001	<0.0001
CCL23	10.00 (9.62-10.41)	9.86 (9.46-10.21)	<0.0001	<0.0001
CCL25	6.61 (6.16-7.01)	6.39 (5.94-6.83)	<0.0001	<0.0001
CCL28	2.81 (2.53-3.15)	2.70 (2.42-3.00)	<0.0001	<0.0001
CD5	5.99 (5.66-6.27)	5.84 (5.54-6.14)	<0.0001	<0.0001
CD6	7.42 (6.99-7.83)	7.34 (6.83-7.73)	0.0038	0.0026
CD40	12.61 (12.12-13.01)	12.44 (11.98-12.89)	0.0002	0.0001
CD244	6.75 (6.44-7.07)	6.63 (6.34-6.89)	<0.0001	<0.0001
CD8A	9.47 (8.86-10.07)	9.33 (8.73-9.91)	0.0016	0.0010
CDCP1	3.97 (3.45-4.49)	3.64 (3.15-4.14)	<0.0001	<0.0001
CSF-1	11.01 (10.82-11.19)	10.93 (10.73-11.12)	<0.0001	<0.0001
CST5	7.30 (6.94-7.67)	7.15 (6.81-7.50)	<0.0001	<0.0001
CX3CL1	4.72 (4.46-5.06)	4.57 (4.20-4.88)	<0.0001	<0.0001
CXCL1	10.39 (9.94-10.88)	10.31 (9.84-10.74)	0.0091	0.0066
CXCL5	12.64 (12.00-13.20)	12.44 (11.75-13.03)	0.0002	0.0001
CXCL6	9.39 (8.94-9.89)	9.24 (8.73-9.70)	<0.0001	<0.0001
CXCL9	7.31 (6.87-7.89)	6.98 (6.49-7.54)	<0.0001	<0.0001
CXCL10	9.96 (9.46-10.54)	9.72 (9.26-10.24)	<0.0001	<0.0001
CXCL11	8.33 (7.63-8.92)	8.06 (7.46-8.69)	<0.0001	<0.0001
DNER	9.65 (9.40-9.86)	9.56 (9.32-9.77)	<0.0001	<0.0001
EN-RAGE	7.27 (6.46-8.18)	7.00 (6.01-7.77)	<0.0001	<0.0001
FGF-19	8.82 (8.04-9.49)	8.53 (7.82-9.24)	<0.0001	<0.0001
FGF-21	5.92 (5.05-6.70)	5.65 (4.82-6.51)	0.0008	0.0005
FGF-23	0.93 (0.84-1.09)	0.93 (0.64-1.15)	0.3844	0.3552
Flt3L	9.77 (9.45-10.13)	9.65 (9.33-9.98)	<0.0001	<0.0001
GDNF	1.44 (1.29-2.04)	1.43 (1.29-1.90)	<0.0001	<0.0001
HGF	9.93 (9.45-10.28)	9.73 (9.29-10.10)	<0.0001	<0.0001
IL-6	2.52 (1.98-3.43)	2.30 (1.71-3.17)	<0.0001	<0.0001
IL-7	3.16 (2.65-3.73)	3.09 (2.53-3.63)	0.0169	0.0132
IL-8	9.40 (7.74-11.96)	9.19 (7.56-11.68)	0.2557	0.2266
IL-10	3.49 (3.09-3.88)	3.36 (3.00-3.76)	0.0002	0.0001
IL-18	9.15 (8.68-9.54)	8.90 (8.48-9.37)	<0.0001	<0.0001
IL-10RA	0.71 (0.48-1.09)	0.66 (0.43-0.98)	0.0079	0.0057

IL-10RB	6.75 (6.50-7.01)	6.64 (6.34-6.87)	<0.0001	<0.0001
IL-15RA	1.51 (1.36-1.74)	1.38 (1.28-1.67)	<0.0001	<0.0001
IL-18R1	9.17 (8.84-9.55)	9.07 (8.68-9.40)	<0.0001	<0.0001
LAP TGF-beta-1	8.22 (7.89-8.55)	8.07 (7.73-8.39)	<0.0001	<0.0001
LIF-R	4.83 (4.59-5.09)	4.71 (4.48-4.92)	<0.0001	<0.0001
MCP-1	12.52 (12.05-13.22)	12.45 (12.00-12.98)	0.0131	0.0098
MCP-2	9.86 (9.34-10.24)	9.69 (9.22-10.09)	0.0001	0.0001
MCP-3	3.89 (2.63-6.38)	3.54 (2.46-6.13)	0.0955	0.0810
MCP-4	15.16 (14.69-15.65)	15.04 (14.51-15.49)	0.0002	0.0001
MMP-1	15.90 (15.32-16.37)	15.91 (15.18-16.43)	0.6484	0.6319
MMP-10	9.91 (9.48-10.30)	9.75 (9.31-10.17)	<0.0001	<0.0001
NT-3	1.37 (1.14-1.65)	1.31 (1.04-1.56)	0.0006	0.0004
OPG	10.48 (10.16-10.79)	10.26 (9.94-10.56)	<0.0001	<0.0001
OSM	7.85 (6.97-8.99)	7.87 (6.97-8.91)	0.8246	0.8246
PD-L1	6.26 (5.97-6.54)	6.10 (5.82-6.38)	<0.0001	<0.0001
SCF	9.69 (9.33-9.98)	9.59 (9.24-9.86)	<0.0001	<0.0001
SIRT2	4.51 (3.61-5.17)	4.38 (3.49-5.10)	0.0794	0.0653
SLAMF1	2.94 (2.66-3.34)	2.87 (2.47-3.21)	0.0002	0.0001
ST1A1	4.20 (2.84-4.92)	4.02 (2.87-4.81)	0.0955	0.0801
STAMBP	5.77 (5.09-6.21)	5.65 (5.05-6.11)	0.0079	0.0057
TGF-alpha	4.91 (4.42-5.41)	4.83 (4.30-5.30)	0.0164	0.0126
TNFB	5.35 (5.03-5.65)	5.35 (4.98-5.66)	0.6034	0.5805
TNFRSF9	7.61 (7.30-7.96)	7.44 (7.11-7.78)	<0.0001	<0.0001
TNFSF14	7.86 (6.97-8.46)	7.71 (6.94-8.33)	0.0161	0.0122
TRAIL	8.40 (8.14-8.66)	8.33 (8.05-8.57)	<0.0001	<0.0001
TRANCE	5.29 (4.85-5.77)	5.31 (4.80-5.75)	0.5578	0.5296
TWEAK	9.27 (8.93-9.53)	9.16 (8.87-9.43)	<0.0001	<0.0001
VEGF-A	12.43 (11.88-12.89)	12.17 (11.69-12.63)	<0.0001	<0.0001
4E-BP1	8.03 (7.23-8.75)	7.83 (6.90-8.60)	0.0034	0.0023
uPA	9.94 (9.68-10.27)	9.84 (9.53-10.11)	<0.0001	<0.0001

Abbreviations: IQR, interquartile range; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1

NOTE: Numbers printed in bold are statistically significant ($p < 0.05$).

^aResults of a Wilcoxon rank-sum test.

^bP-values corrected for multiple testing by Benjamini and Hochberg method.

Supplemental Table 3. Comparison of median biomarker levels between Alzheimer's disease cases (n=163) and controls (n=1278)

Olink Biomarker	Alzheimer's disease (n=163) Median (IQR)	Controls (n=1278) Median (IQR)	p-value ^a	FDR ^b
ADA	6.44 (6.06-6.76)	6.38 (6.02-6.73)	0.2526	0.3041
AXIN1	3.80 (2.89-4.36)	3.60 (2.49-4.26)	0.0197	0.0331
Beta-NGF	0.61 (0.56-0.74)	0.61 (0.43-0.77)	0.3371	0.3916
CASP-8	6.29 (5.31-7.44)	5.93 (5.02-6.85)	0.0012	0.0037
CCL3	7.17 (6.60-7.96)	7.03 (6.49-7.77)	0.0508	0.0704
CCL4	7.36 (6.89-8.12)	7.25 (6.71-7.87)	0.0363	0.0522
CCL11	8.67 (8.29-9.01)	8.54 (8.15-8.89)	0.0007	0.0031
CCL19	9.28 (8.60-9.82)	8.84 (8.31-9.54)	0.0002	0.0010
CCL20	6.81 (6.04-7.61)	6.44 (5.76-7.27)	0.0018	0.0050
CCL23	10.03 (9.63-10.41)	9.86 (9.46-10.21)	<0.0001	0.0004
CCL25	6.51 (6.14-6.92)	6.39 (5.94-6.83)	0.0099	0.0190
CCL28	2.83 (2.54-3.24)	2.70 (2.42-3.00)	<0.0001	0.0004
CD5	5.99 (5.70-6.25)	5.84 (5.54-6.14)	0.0003	0.0013
CD6	7.43 (7.05-7.86)	7.34 (6.83-7.73)	0.0027	0.0069
CD40	12.55 (12.18-13.03)	12.44 (11.98-12.89)	0.0040	0.0093
CD244	6.76 (6.45-7.10)	6.63 (6.34-6.89)	0.0001	0.0009
CD8A	9.45 (8.80-10.00)	9.33 (8.73-9.91)	0.1043	0.1350
CDCP1	3.94 (3.40-4.40)	3.64 (3.15-4.14)	0.0001	0.0009
CSF-1	11.02 (10.82-11.16)	10.93 (10.73-11.12)	0.0029	0.0070
CST5	7.25 (6.95-7.65)	7.15 (6.81-7.50)	0.0009	0.0031
CX3CL1	4.73 (4.46-5.03)	4.57 (4.20-4.88)	<0.0001	0.0001
CXCL1	10.38 (9.88-10.96)	10.31 (9.84-10.74)	0.0872	0.1148
CXCL5	12.63 (12.09-13.25)	12.44 (11.75-13.03)	0.0008	0.0031
CXCL6	9.39 (8.95-9.91)	9.24 (8.73-9.70)	0.0045	0.0101
CXCL9	7.36 (6.87-7.91)	6.98 (6.49-7.54)	<0.0001	<0.0001
CXCL10	9.90 (9.43-10.61)	9.72 (9.26-10.24)	0.0012	0.0037
CXCL11	8.39 (7.69-8.99)	8.06 (7.46-8.69)	0.0008	0.0031
DNER	9.67 (9.40-9.84)	9.56 (9.32-9.77)	0.0021	0.0057
EN-RAGE	7.33 (6.56-8.17)	7.00 (6.01-7.77)	<0.0001	0.0005
FGF-19	8.82 (8.09-9.61)	8.53 (7.82-9.24)	0.0017	0.0050
FGF-21	5.93 (5.00-6.70)	5.65 (4.82-6.51)	0.0478	0.0674
FGF-23	0.93 (0.79-1.04)	0.93 (0.64-1.15)	0.6932	0.7301
Flt3L	9.76 (9.42-10.11)	9.65 (9.33-9.98)	0.0050	0.0107
GDNF	1.44 (1.29-1.99)	1.43 (1.29-1.90)	0.0253	0.0391
HGF	9.89 (9.49-10.26)	9.73 (9.29-10.10)	0.0006	0.0027
IL-6	2.52 (1.90-3.60)	2.30 (1.71-3.17)	0.0139	0.0249
IL-7	3.05 (2.48-3.44)	3.09 (2.53-3.63)	0.4597	0.5114
IL-8	9.38 (7.64-12.41)	9.19 (7.56-11.68)	0.4592	0.5114
IL-10	3.48 (3.08-3.84)	3.36 (3.00-3.76)	0.0331	0.0484
IL-18	9.02 (8.64-9.45)	8.90 (8.48-9.37)	0.0134	0.0247
IL-10RA	0.73 (0.50-1.07)	0.66 (0.43-0.98)	0.0322	0.0479

IL-10RB	6.77 (6.48-6.93)	6.64 (6.34-6.87)	0.0001	0.0008
IL-15RA	1.46 (1.36-1.70)	1.38 (1.28-1.67)	0.0244	0.0385
IL-18R1	9.14 (8.80-9.50)	9.07 (8.68-9.40)	0.0151	0.0265
LAP TGF-beta-1	8.30 (7.91-8.61)	8.07 (7.73-8.39)	<0.0001	0.0001
LIF-R	4.81 (4.50-5.04)	4.71 (4.48-4.92)	0.0008	0.0031
MCP-1	12.49 (12.04-13.22)	12.45 (12.00-12.98)	0.1333	0.1699
MCP-2	9.82 (9.29-10.15)	9.69 (9.22-10.09)	0.0828	0.1109
MCP-3	3.57 (2.43-5.93)	3.54 (2.46-6.13)	0.9037	0.9271
MCP-4	15.15 (14.71-15.68)	15.04 (14.51-15.49)	0.0173	0.0297
MMP-1	15.89 (15.36-16.38)	15.91 (15.18-16.43)	0.5209	0.5561
MMP-10	9.90 (9.48-10.30)	9.75 (9.31-10.17)	0.0029	0.0070
NT-3	1.32 (1.13-1.59)	1.31 (1.04-1.56)	0.4101	0.4695
OPG	10.44 (10.15-10.75)	10.26 (9.94-10.56)	<0.0001	<0.0001
OSM	7.98 (6.94-9.06)	7.87 (6.97-8.91)	0.5066	0.5482
PD-L1	6.25 (5.98-6.54)	6.10 (5.82-6.38)	<0.0001	0.0001
SCF	9.72 (9.38-9.99)	9.59 (9.24-9.86)	0.0002	0.0010
SIRT2	4.52 (3.79-5.18)	4.38 (3.49-5.10)	0.0301	0.0458
SLAMF1	2.90 (2.51-3.31)	2.87 (2.47-3.21)	0.3032	0.3575
ST1A1	4.37 (3.30-5.04)	4.02 (2.87-4.81)	0.0074	0.0151
STAMBP	5.82 (5.22-6.21)	5.65 (5.05-6.11)	0.0093	0.0184
TGF-alpha	4.92 (4.48-5.33)	4.83 (4.30-5.30)	0.0555	0.0756
TNFB	5.39 (5.08-5.69)	5.35 (4.98-5.66)	0.2404	0.2967
TNFRSF9	7.60 (7.35-7.95)	7.44 (7.11-7.78)	<0.0001	0.0003
TNFSF14	7.90 (7.27-8.49)	7.71 (6.94-8.33)	0.0102	0.0193
TRAIL	8.43 (8.13-8.63)	8.33 (8.05-8.57)	0.0054	0.0113
TRANCE	5.32 (4.92-5.79)	5.31 (4.80-5.75)	0.2541	0.3041
TWEAK	9.30 (8.94-9.58)	9.16 (8.87-9.43)	0.0025	0.0065
VEGF-A	12.36 (11.87-12.76)	12.17 (11.69-12.63)	0.0012	0.0037
4E-BP1	8.07 (7.29-8.68)	7.83 (6.90-8.60)	0.0219	0.0361
uPA	9.97 (9.67-10.30)	9.84 (9.53-10.11)	<0.0001	0.0004

Abbreviations: IQR, interquartile range; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1

NOTE: Numbers printed in bold are statistically significant ($p < 0.05$).

^aResults of a Wilcoxon rank-sum test. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

^bP-values corrected for multiple testing by Benjamini and Hochberg method.

Supplemental Table 4. Comparison of median biomarker levels between vascular dementia cases (n=195) and controls (n=1278)

Olink Biomarker	Vascular dementia (n=195) Median (IQR)	Controls (n=1278) Median (IQR)	p-value ^a	FDR ^b
ADA	6.45 (6.06-6.75)	6.38 (6.02-6.73)	0.2154	0.2701
AXIN1	3.70 (2.39-4.37)	3.60 (2.49-4.26)	0.5743	0.6312
Beta-NGF	0.61 (0.59-0.67)	0.61 (0.43-0.77)	0.4956	0.5758
CASP-8	6.04 (5.12-7.10)	5.93 (5.02-6.85)	0.2717	0.3302
CCL3	7.30 (6.76-8.11)	7.03 (6.49-7.77)	0.0006	0.0015
CCL4	7.53 (6.88-8.10)	7.25 (6.71-7.87)	0.0025	0.0050
CCL11	8.68 (8.27-9.06)	8.54 (8.15-8.89)	<0.0001	0.0003
CCL19	9.06 (8.44-9.73)	8.84 (8.31-9.54)	0.0114	0.0166
CCL20	6.79 (6.03-7.74)	6.44 (5.76-7.27)	<0.0001	0.0002
CCL23	9.98 (9.63-10.44)	9.86 (9.46-10.21)	<0.0001	0.0004
CCL25	6.63 (6.09-7.06)	6.39 (5.94-6.83)	0.0001	0.0004
CCL28	2.82 (2.55-3.07)	2.70 (2.42-3.00)	0.0005	0.0014
CD5	6.06 (5.71-6.31)	5.84 (5.54-6.14)	<0.0001	<0.0001
CD6	7.45 (6.97-7.78)	7.34 (6.83-7.73)	0.0529	0.0733
CD40	12.62 (12.12-13.03)	12.44 (11.98-12.89)	0.0069	0.0106
CD244	6.77 (6.44-7.09)	6.63 (6.34-6.89)	<0.0001	0.0002
CD8A	9.49 (8.95-10.11)	9.33 (8.73-9.91)	0.0057	0.0091
CDCP1	4.01 (3.47-4.61)	3.64 (3.15-4.14)	<0.0001	<0.0001
CSF-1	11.03 (10.85-11.19)	10.93 (10.73-11.12)	<0.0001	0.0004
CST5	7.28 (6.94-7.64)	7.15 (6.81-7.50)	0.0008	0.0019
CX3CL1	4.71 (4.42-5.05)	4.57 (4.20-4.88)	<0.0001	<0.0001
CXCL1	10.48 (10.07-10.89)	10.31 (9.84-10.74)	0.0027	0.0051
CXCL5	12.69 (12.04-13.21)	12.44 (11.75-13.03)	0.0015	0.0032
CXCL6	9.38 (8.99-9.91)	9.24 (8.73-9.70)	0.0006	0.0015
CXCL9	7.34 (6.89-7.98)	6.98 (6.49-7.54)	<0.0001	<0.0001
CXCL10	10.00 (9.50-10.73)	9.72 (9.26-10.24)	<0.0001	<0.0001
CXCL11	8.30 (7.68-8.89)	8.06 (7.46-8.69)	0.0015	0.0032
DNER	9.64 (9.39-9.87)	9.56 (9.32-9.77)	0.0019	0.0040
EN-RAGE	7.22 (6.48-8.18)	7.00 (6.01-7.77)	0.0002	0.0005
FGF-19	8.91 (8.02-9.48)	8.53 (7.82-9.24)	0.002	0.0041
FGF-21	5.94 (5.18-6.71)	5.65 (4.82-6.51)	0.0028	0.0053
FGF-23	0.93 (0.79-1.02)	0.93 (0.64-1.15)	0.8527	0.8749
Flt3L	9.78 (9.47-10.15)	9.65 (9.33-9.98)	0.0002	0.0005
GDNF	1.42 (1.29-2.06)	1.43 (1.29-1.90)	0.0063	0.0100
HGF	9.97 (9.50-10.26)	9.73 (9.29-10.10)	<0.0001	<0.0001
IL-6	2.57 (1.99-3.43)	2.30 (1.71-3.17)	0.0012	0.0026
IL-7	3.28 (2.75-3.78)	3.09 (2.53-3.63)	0.0031	0.0056
IL-8	9.42 (7.98-12.28)	9.19 (7.56-11.68)	0.1985	0.2529
IL-10	3.53 (3.11-3.97)	3.36 (3.00-3.76)	0.0006	0.0015
IL-18	9.16 (8.69-9.55)	8.90 (8.48-9.37)	<0.0001	0.0002
IL-10RA	0.71 (0.47-1.10)	0.66 (0.43-0.98)	0.0681	0.0928

IL-10RB	6.74 (6.48-7.01)	6.64 (6.34-6.87)	<0.0001	0.0004
IL-15RA	1.55 (1.36-1.73)	1.38 (1.28-1.67)	<0.0001	0.0003
IL-18R1	9.20 (8.87-9.56)	9.07 (8.68-9.40)	<0.0001	0.0002
LAP TGF-beta-1	8.20 (7.89-8.50)	8.07 (7.73-8.39)	0.0001	0.0004
LIF-R	4.83 (4.62-5.10)	4.71 (4.48-4.92)	<0.0001	<0.0001
MCP-1	12.54 (11.99-13.21)	12.45 (12.00-12.98)	0.0722	0.0967
MCP-2	9.92 (9.38-10.30)	9.69 (9.22-10.09)	0.0003	0.0009
MCP-3	3.85 (2.65-6.56)	3.54 (2.46-6.13)	0.1077	0.1419
MCP-4	15.15 (14.70-15.68)	15.04 (14.51-15.49)	0.0049	0.0082
MMP-1	15.91 (15.27-16.36)	15.91 (15.18-16.43)	0.9038	0.9154
MMP-10	9.95 (9.57-10.42)	9.75 (9.31-10.17)	<0.0001	<0.0001
NT-3	1.40 (1.13-1.65)	1.31 (1.04-1.56)	0.0044	0.0075
OPG	10.48 (10.15-10.79)	10.26 (9.94-10.56)	<0.0001	<0.0001
OSM	7.77 (7.09-9.10)	7.87 (6.97-8.91)	0.7958	0.8382
PD-L1	6.27 (5.95-6.58)	6.10 (5.82-6.38)	<0.0001	<0.0001
SCF	9.70 (9.32-9.99)	9.59 (9.24-9.86)	0.0050	0.0082
SIRT2	4.51 (3.45-5.08)	4.38 (3.49-5.10)	0.9709	0.9709
SLAMF1	2.93 (2.66-3.34)	2.87 (2.47-3.21)	0.0096	0.0143
ST1A1	4.13 (2.70-4.85)	4.02 (2.87-4.81)	0.5753	0.6312
STAMBP	5.71 (5.04-6.13)	5.65 (5.05-6.11)	0.6045	0.6541
TGF-alpha	4.95 (4.49-5.51)	4.83 (4.30-5.30)	0.0192	0.0275
TNFB	5.35 (5.01-5.62)	5.35 (4.98-5.66)	0.8368	0.8698
TNFRSF9	7.63 (7.29-8.01)	7.44 (7.11-7.78)	<0.0001	<0.0001
TNFSF14	7.89 (6.87-8.49)	7.71 (6.94-8.33)	0.0518	0.0731
TRAIL	8.38 (8.14-8.68)	8.33 (8.05-8.57)	0.0030	0.0055
TRANCE	5.29 (4.83-5.86)	5.31 (4.80-5.75)	0.3947	0.4725
TWEAK	9.25 (8.92-9.54)	9.16 (8.87-9.43)	0.0033	0.0058
VEGF-A	12.45 (11.87-12.95)	12.17 (11.69-12.63)	<0.0001	<0.0001
4E-BP1	8.00 (7.21-8.65)	7.83 (6.90-8.60)	0.2272	0.2805
uPA	9.94 (9.66-10.28)	9.84 (9.53-10.11)	0.0003	0.0009

Abbreviations: IQR, interquartile range; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1

NOTE: Numbers printed in bold are statistically significant ($p < 0.05$).

^aResults of a Wilcoxon rank-sum test. Study participants with other (e.g. AD) or unknown dementia forms were excluded.

^bP-values corrected for multiple testing by Benjamini and Hochberg method.

Supplemental Table 5. Non-significant associations of Olink Inflammation panel biomarker levels with **all-cause dementia** incidence (FDR $\geq$ 0.05)

Olink Biomarker	Value of 1 SD	All-cause dementia (n=504 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
Beta-NGF	0.397	0.97 (0.86-1.11)	0.6887	0.6984
CD8A	0.944	1.13 (1.00-1.27)	0.0492	0.0581
FGF-21	1.315	1.11 (0.99-1.25)	0.0716	0.0818
FGF-23	0.449	0.99 (0.88-1.11)	0.8587	0.8587
IL-6	1.871	1.10 (0.98-1.23)	0.1092	0.1210
IL-8	2.570	1.09 (0.97-1.22)	0.1471	0.1605
IL-12B	0.795	1.10 (0.98-1.24)	0.1086	0.1210
MCP-1	1.001	1.12 (1.00-1.26)	0.0469	0.0563
MCP-3	2.846	1.05 (0.94-1.18)	0.3626	0.3784
MMP-1	0.981	1.04 (0.93-1.18)	0.4651	0.4784
OSM	1.501	1.08 (0.96-1.21)	0.2165	0.2292
SLAMF1	0.633	1.12 (1.00-1.27)	0.0506	0.0588
TNFB	0.592	1.08 (0.96-1.22)	0.1823	0.1959
4E-BP1	1.300	1.13 (1.00-1.27)	0.0457	0.0558

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Supplemental Table 6. Non-significant associations of Olink Inflammation panel biomarker levels with **Alzheimer's disease** incidence (FDR ≥ 0.05)

Olink Biomarker	Value of 1 SD	Alzheimer's disease (n=163 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
ADA	0.635	1.07 (0.90-1.28)	0.4191	0.4572
AXIN1	1.140	1.24 (1.04-1.50)	0.0196	0.0564
Beta-NGF	0.397	0.98 (0.81-1.18)	0.8200	0.8315
CCL3	1.508	1.11 (0.94-1.31)	0.2045	0.2727
CCL4	1.099	1.16 (0.98-1.38)	0.0792	0.1326
CCL11	0.697	1.26 (1.03-1.53)	0.0215	0.0594
CCL19	1.199	1.24 (1.04-1.47)	0.0162	0.0501
CCL20	1.540	1.17 (1.00-1.38)	0.0520	0.0891
CCL25	0.763	1.08 (0.90-1.30)	0.4293	0.4613
CD5	0.523	1.24 (1.03-1.49)	0.0253	0.0594
CD40	0.734	1.24 (1.03-1.50)	0.0259	0.0594
CD8A	0.944	1.09 (0.91-1.32)	0.3392	0.3939
CDCP1	0.894	1.16 (0.96-1.40)	0.1324	0.1945
CSF-1	0.425	1.22 (1.00-1.50)	0.0512	0.0891
CST5	0.698	1.25 (1.03-1.51)	0.0226	0.0594
CXCL1	0.901	1.15 (0.97-1.37)	0.1021	0.1598
CXCL9	0.953	1.23 (1.02-1.48)	0.0264	0.0594
CXCL10	0.953	1.09 (0.91-1.31)	0.3288	0.3881
CXCL11	1.051	1.21 (1.01-1.45)	0.0341	0.0701
FGF-19	1.089	1.21 (1.02-1.45)	0.0328	0.0695
FGF-21	1.315	1.10 (0.91-1.32)	0.3247	0.3881
FGF-23	0.449	0.87 (0.72-1.06)	0.1694	0.2301
Flt3L	0.629	1.18 (0.98-1.41)	0.0875	0.1400
GDNF	0.506	1.06 (0.88-1.28)	0.5480	0.5802
IL-6	1.871	1.10 (0.93-1.30)	0.2483	0.3136
IL-7	0.798	0.97 (0.81-1.16)	0.7445	0.7658
IL-8	2.570	1.07 (0.90-1.28)	0.4121	0.4565
IL-10	0.863	1.08 (0.91-1.29)	0.3790	0.4331
IL-18	0.763	1.22 (1.01-1.48)	0.0393	0.0765
IL-12B	0.795	1.15 (0.96-1.38)	0.1361	0.1960
IL-10RA	0.788	1.13 (0.96-1.33)	0.1555	0.2195
IL-15RA	0.359	1.12 (0.93-1.35)	0.2414	0.3104
IL-18R1	0.602	1.18 (0.98-1.42)	0.0862	0.1400
MCP-1	1.001	1.13 (0.95-1.34)	0.1663	0.2301
MCP-2	0.769	1.08 (0.90-1.31)	0.3892	0.4379
MCP-3	2.846	0.99 (0.84-1.18)	0.9418	0.9418
MCP-4	0.927	1.22 (1.00-1.49)	0.0465	0.0873
MMP-1	0.981	1.10 (0.92-1.32)	0.2830	0.3512
MMP-10	0.761	1.21 (1.01-1.45)	0.0393	0.0765
NT-3	0.544	1.10 (0.92-1.31)	0.2878	0.3512
OPG	0.609	1.28 (1.05-1.57)	0.0167	0.0501
OSM	1.501	1.12 (0.94-1.33)	0.2121	0.2777
SCF	0.624	1.26 (1.03-1.56)	0.0277	0.0604
SIRT2	1.157	1.20 (1.00-1.43)	0.0517	0.0891
SLAMF1	0.633	1.05 (0.87-1.27)	0.5886	0.6142
TNFB	0.592	1.17 (0.96-1.41)	0.1144	0.1716
TNFRSF9	0.636	1.24 (1.03-1.50)	0.0250	0.0594
TNFSF14	1.064	1.24 (1.03-1.49)	0.0245	0.0594
TRANCE	0.753	1.21 (1.00-1.45)	0.0473	0.0873
4E-BP1	1.300	1.16 (0.97-1.39)	0.1135	0.1716

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Supplemental Table 7. Non-significant associations of Olink Inflammation panel biomarker levels with **vascular dementia** incidence (FDR ≥ 0.05)

Olink Biomarker	Value of 1 SD	Vascular dementia (n=195 cases)		
		OR (95% CI) per 1 SD ^a	p-value per 1 SD	FDR corrected p-value ^b
ADA	0.635	1.08 (0.92-1.27)	0.3647	0.4376
AXIN1	1.140	1.06 (0.90-1.25)	0.4768	0.5364
Beta-NGF	0.397	0.98 (0.83-1.16)	0.8471	0.8839
CASP-8	1.364	1.08 (0.92-1.28)	0.3416	0.4198
CCL3	1.508	1.17 (1.00-1.36)	0.0473	0.0811
CCL4	1.099	1.19 (1.01-1.39)	0.0329	0.0623
CCL19	1.199	1.08 (0.92-1.27)	0.3440	0.4198
CCL20	1.540	1.19 (1.02-1.39)	0.0260	0.0520
CCL25	0.763	1.18 (1.00-1.41)	0.0564	0.0864
CCL28	0.548	1.17 (1.00-1.38)	0.0503	0.0823
CD6	0.757	1.15 (0.97-1.37)	0.0966	0.1419
CD40	0.734	1.18 (1.00-1.40)	0.0555	0.0864
CD8A	0.944	1.14 (0.96-1.35)	0.1316	0.1858
CSF-1	0.425	1.24 (1.03-1.49)	0.0240	0.0508
CST5	0.698	1.08 (0.91-1.27)	0.3916	0.4622
CXCL11	1.051	1.21 (1.02-1.43)	0.0250	0.0514
FGF-19	1.089	1.18 (1.01-1.39)	0.0404	0.0727
FGF-21	1.315	1.14 (0.96-1.35)	0.1277	0.1839
FGF-23	0.449	0.96 (0.83-1.12)	0.6277	0.6745
GDNF	0.506	1.16 (0.99-1.35)	0.0655	0.0983
IL-6	1.871	1.11 (0.95-1.30)	0.1709	0.2322
IL-8	2.570	1.11 (0.94-1.30)	0.2125	0.2732
IL-12B	0.795	1.13 (0.96-1.34)	0.1397	0.1934
IL-10RA	0.788	1.16 (1.00-1.34)	0.0501	0.0823
IL-10RB	0.533	1.21 (1.01-1.44)	0.0372	0.0687
IL-15RA	0.359	1.20 (1.02-1.42)	0.0278	0.0541
MCP-1	1.001	1.11 (0.95-1.30)	0.2037	0.2667
MCP-3	2.846	1.06 (0.90-1.24)	0.5008	0.5547
MMP-1	0.981	1.00 (0.86-1.17)	0.9633	0.9769
OSM	1.501	1.07 (0.91-1.26)	0.4036	0.4687
SCF	0.624	1.12 (0.94-1.32)	0.1974	0.2632
SIRT2	1.157	1.00 (0.85-1.18)	0.9941	0.9941
SLAMF1	0.633	1.07 (0.91-1.26)	0.4175	0.4771
ST1A1	1.304	1.09 (0.92-1.29)	0.3037	0.3836
STAMBP	0.833	1.04 (0.88-1.22)	0.6686	0.7079
TNFB	0.592	1.05 (0.89-1.24)	0.5723	0.6243
TNFSF14	1.064	1.18 (1.00-1.39)	0.0546	0.0864
TRANCE	0.753	1.19 (1.00-1.40)	0.0455	0.0799
4E-BP1	1.300	1.00 (0.85-1.19)	0.9593	0.9769

Abbreviations: SD, standard deviation; CI, confidence interval; FDR, false discovery rate; For biomarker abbreviations, see Supplemental Table 1.

^a Multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype. Study participants with other (e.g. AD) or unknown dementia forms were excluded.

^b P-values corrected for multiple testing by the Benjamini and Hochberg method.

Supplemental Table 8. Olink Inflammation Panel Biomarkers in the CX3CL1 cluster

No.	Biomarker	Spearman's r with CX3CL1 ^a
1	IL-10RB ^{b,c}	0.672
2	LIF-R ^{b,c,d}	0.661
3	OPG ^{b,d}	0.621
4	CCL23 ^{b,c,d}	0.603
5	PD-L1 ^{b,c,d}	0.602
6	TNFRSF9 ^{b,d}	0.600
7	CSF-1 ^b	0.589
8	IL-15RA ^b	0.568
9	TWEAK ^{b,c,d}	0.561
10	CCL25 ^b	0.555
11	TRAIL ^{b,c,d}	0.550
12	Flt3L ^b	0.546
13	DNER ^{b,c,d}	0.537
14	uPA ^{b,c,d}	0.523
15	CD244 ^{b,c,d}	0.522
16	CD5 ^{b,d}	0.522
17	SCF ^b	0.508
18	IL-12B	0.506

^aAll biomarkers with $r > 0.5$ with CX3CL1 were selected for the cluster.

^bSignificantly associated with all-cause dementia.

^cSignificantly associated with Alzheimer's disease.

^dSignificantly associated with vascular dementia.

Note: For biomarker abbreviations, see Supplemental Table 1.

Supplemental Table 9. Olink Inflammation Panel Biomarkers in the EN-RAGE cluster

No.	Biomarker	Spearman's r with EN-RAGE ^a
1	TNFSF14 ^b	0.817
2	OSM	0.799
3	CASP-8 ^{b,c}	0.784
4	CD40 ^b	0.753
5	STAMBP ^{b,c}	0.750
6	HGF ^{b,c,d}	0.735
7	SIRT2 ^b	0.731
8	TGF-alpha ^{b,c,d}	0.715
9	IL-8	0.705
10	AXIN1 ^b	0.675
11	CCL3 ^b	0.664
12	uPA ^{b,c,d}	0.643
13	ADA ^b	0.632
14	CCL4 ^b	0.620
15	CD244 ^{b,c,d}	0.599
16	VEGF-A ^{b,c,d}	0.593
17	MCP-3	0.591
18	CSF-1 ^b	0.574
19	ST1A1 ^{b,c}	0.561
20	CXCL11 ^b	0.559
21	MCP-1	0.552
22	IL-6	0.542
23	CD6 ^{b,c}	0.536
24	CD5 ^{b,d}	0.535
25	IL-18 ^{b,d}	0.517
26	CXCL1 ^{b,d}	0.511

^aAll biomarkers with $r > 0.5$ with EN-RAGE were selected for the cluster.

^bSignificantly associated with all-cause dementia.

^cSignificantly associated with Alzheimer's disease.

^dSignificantly associated with vascular dementia.

Note: For biomarker abbreviations, see Supplemental Table 1.

Supplemental Table 10. Olink Inflammation Panel Biomarkers in the LAP TGF-beta-1 cluster

No.	Biomarker	Spearman's r with LAP TGF-beta-1 ^a
1	HGF ^{b,c,d}	0.601
2	CD244 ^{b,c,d}	0.577
3	TWEAK ^{b,c,d}	0.560
4	uPA ^{b,c,d}	0.557
5	OPG ^{b,d}	0.543
6	LIF-R ^{b,c,d}	0.540
7	CSF-1	0.539
8	IL-10RB ^{b,c}	0.539
9	PD-L1 ^{b,c,d}	0.518
10	VEGF-A ^{b,d}	0.516
11	DNER ^{b,c,d}	0.513
12	CD5 ^{b,d}	0.510
13	CCL11 ^{b,d}	0.509
14	MCP-4 ^{b,d}	0.504
15	CXCL6 ^{b,c,d}	0.501
16	CD40 ^b	0.500

^aAll biomarkers with $r > 0.5$ with LAP TGF-beta-1 were selected for the cluster.

^bSignificantly associated with all-cause dementia.

^cSignificantly associated with Alzheimer's disease.

^dSignificantly associated with vascular dementia.

Note: For biomarker abbreviations, see Supplemental Table 1.

Supplemental Table 11. Olink Inflammation Panel Biomarkers in the VEGF-A cluster

No.	Biomarker	Spearman's r with VEGF-A ^a
1	HGF ^{b,c,d}	0.680
2	CD40 ^b	0.646
3	CSF-1	0.620
4	uPA ^{b,c,d}	0.608
5	EN-RAGE ^{b,c,d}	0.593
6	CD244 ^{b,c,d}	0.584
7	MCP-1	0.563
8	OSM	0.561
9	CXCL1 ^{b,d}	0.558
10	CCL3 ^b	0.556
11	TGF-α ^{b,c,d}	0.554
12	TNFSF14 ^b	0.551
13	IL-6	0.538
14	CCL4 ^b	0.534
15	STAMBP ^{b,c}	0.531
16	PD-L1 ^{b,c,d}	0.529
17	IL-10RB ^{b,c}	0.526
18	CD5 ^{b,d}	0.522
19	TNFRSF9 ^{b,d}	0.520
20	CXCL11 ^b	0.519
21	IL-10 ^{b,d}	0.518
22	OPG ^{b,d}	0.518
23	SIRT2 ^b	0.518
24	LAP TGF-β-1 ^{b,c,d}	0.516
25	ADA ^b	0.514
26	TWEAK ^{b,c,d}	0.504
27	IL-18R1 ^{b,d}	0.504
28	CCL11 ^{b,d}	0.502

^aAll biomarkers with $r > 0.5$ with VEGF-A were selected for the cluster.

^bSignificantly associated with all-cause dementia.

^cSignificantly associated with Alzheimer's disease.

^dSignificantly associated with vascular dementia.

For biomarker abbreviations, see Supplemental Table 1.

Supplemental Table 12. Exploratory subgroup and sensitivity analyses for the association of CX3CL1 and all-cause dementia

Group	n _{total}	n _{cases}	OR (95% CI) ^a	p-value interaction
Total cohort	1782	504	1.41 (1.24-1.60)	
Stratified by age				0.2767
<68 years	1258	254	1.51 (1.29-1.78)	
≥68 years	524	250	1.49 (1.22-1.83)	
Stratified by sex				0.6705
Women	965	262	1.36 (1.14-1.61)	
Men	817	242	1.48 (1.23-1.78)	
Stratified by obesity				0.9649
BMI < 30 kg/m ²	479	144	1.46 (1.14-1.87)	
BMI ≥ 30 kg/m ²	1303	360	1.40 (1.21-1.62)	
Stratified by diabetes				0.0804
No	1489	394	1.47 (1.28-1.69)	
Yes	293	110	1.19 (0.87-1.64)	
Stratified by CVD				0.8759
No	1373	350	1.40 (1.21-1.63)	
Yes	409	154	1.45 (1.13-1.86)	
Stratified by APOE ε4				0.5879
Negative	1276	313	1.42 (1.22-1.66)	
Positive	506	193	1.34 (1.07-1.69)	
Stratified by time of diagnosis				NA
In first 10 years of FUP	1498	220	1.65 (1.36-2.00)	
In year 11-19 of FUP	1562	284	1.28 (1.10-1.48)	
Excluding subjects free of dementia who died prior to 80th birthday				NA
No	1782	504	1.41 (1.24-1.60)	
Yes	1601	504	1.47 (1.29-1.67)	
Excluding subjects with sign of acute infection (CRP level >20mg/L)				NA
No	1782	504	1.41 (1.24-1.60)	
Yes	1745	497	1.41 (1.24-1.60)	

Abbreviations: CX3CL1, Fractalkine; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; APOE, apolipoprotein E; CRP, C-reactive protein;

NOTE: Numbers printed in bold are statistically significant (p < 0.05).

^aResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, APOE genotype.

Supplemental Table 13. Exploratory subgroup and sensitivity analyses for the association of EN-RAGE and all-cause dementia

Group	n _{total}	n _{cases}	OR (95% CI) ^a	p-value interaction
Total cohort	1782	504	1.41 (1.25-1.60)	
Stratified by age				0.3201
<68 years	1258	254	1.41 (1.21-1.64)	
≥68 years	524	250	1.34 (1.11-1.61)	
Stratified by sex				0.2769
Women	965	262	1.55 (1.30-1.85)	
Men	817	242	1.32 (1.11-1.56)	
Stratified by obesity				0.2911
BMI < 30 kg/m ²	479	144	1.31 (1.04-1.66)	
BMI ≥ 30 kg/m ²	1303	360	1.48 (1.28-1.71)	
Stratified by diabetes				0.3445
No	1489	394	1.45 (1.27-1.66)	
Yes	293	110	1.31 (0.99-1.74)	
Stratified by CVD				0.9128
No	1373	350	1.43 (1.24-1.66)	
Yes	409	154	1.37 (1.09-1.73)	
Stratified by APOE ε4				0.0241
Negative	1276	313	1.56 (1.34-1.81)	
Positive	506	193	1.16 (0.94-1.42)	
Stratified by time of diagnosis				NA
In first 10 years of FUP	1498	220	1.46 (1.22-1.73)	
In year 11-19 of FUP	1562	284	1.36 (1.18-1.57)	
Excluding subjects free of dementia who died prior to 80th birthday				NA
No	1782	504	1.41 (1.25-1.60)	
Yes	1601	504	1.49 (1.31-1.68)	
Excluding subjects with sign of acute infection (CRP level >20mg/L)				NA
No	1782	504	1.41 (1.25-1.60)	
Yes	1745	497	1.43 (1.27-1.62)	

Abbreviations: EN-RAGE, Protein S100-A12; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; APOE, apolipoprotein E; CRP, C-reactive protein;

NOTE: Numbers printed in bold are statistically significant (p < 0.05).

^a Results of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, APOE genotype.

Supplemental Table 14. Exploratory subgroup and sensitivity analyses for the association of EN-RAGE and Alzheimer's disease

Group	n _{total}	n _{cases}	OR (95% CI) ^a	p-value interaction
Total cohort	1782	163	1.51 (1.25-1.83)	
Stratified by age				0.7589
<68 years	1258	88	1.43 (1.12-1.81)	
≥68 years	524	75	1.54 (1.12-2.11)	
Stratified by sex				0.6325
Women	965	95	1.46 (1.14-1.88)	
Men	817	68	1.58 (1.16-2.15)	
Stratified by obesity				0.9321
BMI < 30 kg/m ²	479	53	1.53 (1.06-2.22)	
BMI ≥ 30 kg/m ²	1303	110	1.50 (1.19-1.89)	
Stratified by diabetes				0.2142
No	1489	131	1.40 (1.14-1.72)	
Yes	293	32	2.01 (1.22-3.30) ^b	
Stratified by CVD				0.4966
No	1373	124	1.56 (1.25-1.95)	
Yes	409	39	1.31 (0.90-1.91) ^b	
Stratified by APOE ε4				0.0798
Negative	1276	87	1.78 (1.35-2.33)	
Positive	506	76	1.22 (0.93-1.61)	
Stratified by time of diagnosis				NA
In first 10 years of FUP	1699	80	1.79 (1.34-2.36)	
In year 11-19 of FUP	1702	83	1.31 (1.02-1.67)	
Excluding subjects free of dementia who died prior to 80th birthday				NA
No	1782	163	1.51 (1.25-1.83)	
Yes	1601	163	1.58 (1.30-1.92)	
Excluding subjects with sign of acute infection (CRP level >20mg/L)				NA
No	1782	163	1.51 (1.25-1.83)	
Yes	1745	160	1.51 (1.24-1.83)	

Abbreviations: EN-RAGE, Protein S100-A12; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; APOE, apolipoprotein E; CRP, C-reactive protein;

NOTE: Numbers printed in bold are statistically significant (p < 0.05).

^aResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, *APOE* genotype. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

^bResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

Supplemental Table 15. Exploratory subgroup and sensitivity analyses for the association of LAP TGF-beta-1 and Alzheimer's disease

Group	n _{total}	n _{cases}	OR (95% CI) ^a	p-value interaction
Total cohort	1782	163	1.46 (1.21-1.76)	
Stratified by age				0.6941
<68 years	1258	88	1.41 (1.12-1.78)	
≥68 years	524	75	1.49 (1.09-2.03)	
Stratified by sex				0.9685
Women	965	95	1.51 (1.17-1.94)	
Men	817	68	1.47 (1.09-1.97)	
Stratified by obesity				0.3398
BMI < 30 kg/m ²	479	53	1.30 (0.88-1.93)	
BMI ≥ 30 kg/m ²	1303	110	1.53 (1.23-1.91)	
Stratified by diabetes				0.7049
No	1489	131	1.48 (1.20-1.84)	
Yes	293	32	1.64 (1.05-2.54) ^b	
Stratified by CVD				0.3792
No	1373	124	1.55 (1.25-1.93)	
Yes	409	39	1.28 (0.88-1.85) ^b	
Stratified by APOE ε4				0.3987
Negative	1276	87	1.59 (1.21-2.07)	
Positive	506	76	1.33 (1.02-1.74)	
Stratified by time of diagnosis				NA
In first 10 years of FUP	1699	80	1.47 (1.13-1.91)	
In year 11-19 of FUP	1702	83	1.46 (1.15-1.85)	
Excluding subjects free of dementia who died prior to 80th birthday				NA
No	1782	163	1.46 (1.21-1.76)	
Yes	1601	163	1.56 (1.28-1.90)	
Excluding subjects with sign of acute infection (CRP level >20mg/L)				NA
No	1782	163	1.46 (1.21-1.76)	
Yes	1745	160	1.46 (1.21-1.77)	

Abbreviations: LAP TGF-beta-1, Latency-associated peptide transforming growth factor beta-1; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; APOE, apolipoprotein E; CRP, C-reactive protein;

NOTE: Numbers printed in bold are statistically significant (p < 0.05).

^aResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, APOE genotype. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

^bResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes. Study participants with other (e.g. VD) or unknown dementia forms were excluded.

Supplemental Table 16. Exploratory subgroup and sensitivity analyses for the association of VEGF-A and vascular dementia

Group	n _{total}	n _{cases}	OR (95% CI) ^a	p-value interaction
Total cohort	1782	195	1.43 (1.20-1.70)	
Stratified by age				0.6534
<68 years	524	98	1.24 (1.00-1.54)	
≥68 years	1258	97	1.75 (1.31-2.34)	
Stratified by sex				0.7408
Women	965	100	1.41 (1.10-1.79)	
Men	817	95	1.45 (1.13-1.86)	
Stratified by obesity				0.5126
BMI < 30 kg/m ²	479	49	1.34 (0.95-1.90)	
BMI ≥ 30 kg/m ²	1303	146	1.48 (1.21-1.81)	
Stratified by diabetes				0.7305
No	1489	147	1.44 (1.19-1.74)	
Yes	293	48	1.40 (0.91-2.16)	
Stratified by CVD				0.1381
No	1373	124	1.34 (1.08-1.65)	
Yes	409	71	1.74 (1.24-2.44)	
Stratified by APOE ε4				0.5134
Negative	1276	127	1.47 (1.19-1.82)	
Positive	506	68	1.32 (0.97-1.81)	
Stratified by time of diagnosis				NA
In first 10 years of FUP	1666	79	1.75 (1.33-2.32)	
In year 11-19 of FUP	1703	116	1.29 (1.04-1.59)	
Excluding subjects free of dementia who died prior to 80th birthday				NA
No	1782	195	1.43 (1.20-1.70)	
Yes	1601	195	1.52 (1.27-1.82)	
Excluding subjects with sign of acute infection (CRP level >20mg/L)				NA
No	1782	195	1.43 (1.20-1.70)	
Yes	1745	192	1.46 (1.22-1.74)	

Abbreviations: VEGF-A, Vascular endothelial growth factor-A; OR, odds ratio; CI, confidence interval; CVD, cardiovascular disease; APOE, apolipoprotein E; CRP, C-reactive protein;

NOTE: Numbers printed in bold are statistically significant (p < 0.05).

^aResults of multivariate logistic regression model adjusted for age (continuously), sex, education, physical activity, BMI (categorical), CVD, diabetes, depression, APOE genotype. Study participants with other (e.g. AD) or unknown dementia forms were excluded.

References

1. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS one*. 2014;9(4):e95192.
2. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic acids research*. 2011;39(15):e102.
3. Proseek® Multiplex Inflammation I^{96x96} https://www.olink.com/content/uploads/2015/12/0993-v1.1-Proseek-Multiplex-Inflammation-I-Data-Package_final.pdf. Published 2016. Accessed 25 June 2020.
4. Team OPDS. OlinkAnalyze. <https://github.com/Olink-Proteomics/OlinkRPackage/tree/master/OlinkAnalyze>. Published 2018. Accessed 07/03/2021.
5. Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer's disease. *EMBO molecular medicine*. 2018;10(5).
6. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials. *Methods Inf Med*. 2005;44(4):561-571.
7. Finneran DJ, Nash KR. Neuroinflammation and fractalkine signaling in Alzheimer's disease. *Journal of neuroinflammation*. 2019;16(1):30.
8. Pawelec P, Ziemka-Nalecz M, Syceka J, Zalewska T. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. *Cells*. 2020;9(10).
9. Kulczyńska-Przybik A, Słowik A, Mroczko P, et al. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. *Current Alzheimer research*. 2020.
10. Cristóvão JS, Gomes CM. S100 Proteins in Alzheimer's Disease. *Frontiers in Neuroscience*. 2019;13(463).
11. Shepherd CE, Goyette J, Utter V, et al. Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. *Neurobiology of aging*. 2006;27(11):1554-1563.
12. He Y-Y, Yan W, Liu C-L, et al. Usefulness of S100A12 as a prognostic biomarker for adverse events in patients with heart failure. *Clinical Biochemistry*. 2015;48(4):329-333.
13. Zhao P, Wu M, Yu H, et al. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. *J Investig Med*. 2013;61(5):861-866.
14. Feng MJ, Ning WB, Wang W, et al. Serum S100A12 as a prognostic biomarker of severe traumatic brain injury. *Clinica chimica acta; international journal of clinical chemistry*. 2018;480:84-91.
15. Teissier T, Boulanger É. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. *Biogerontology*. 2019;20(3):279-301.
16. Derk J, MacLean M, Juranek J, Schmidt AM. The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration. *J Alzheimers Dis Parkinsonism*. 2018;8(1):421.
17. Khalil N. TGF-β: from latent to active. *Microbes and Infection*. 1999;1(15):1255-1263.
18. Estrada LD, Oliveira-Cruz L, Cabrera D. Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer's Disease. *Curr Protein Pept Sci*. 2018;19(12):1180-1188.
19. Fang XX, Sun GL, Zhou Y, Qiu YH, Peng YP. TGF-β1 protection against Aβ1-42-induced hippocampal neuronal inflammation and apoptosis by TβR-I. *Neuroreport*. 2018;29(2):141-146.

20. Diniz LP, Matias I, Siqueira M, Stipursky J, Gomes FCA. Astrocytes and the TGF- β 1 Pathway in the Healthy and Diseased Brain: a Double-Edged Sword. *Molecular Neurobiology*. 2019;56(7):4653-4679.
21. Khedr EM, Gomaa AMS, Ahmed OG, Sayed HMM, Gamea A. Cognitive Impairment, P300, and Transforming Growth Factor β 1 in Different Forms of Dementia. *Journal of Alzheimer's disease : JAD*. 2020;78(2):837-845.
22. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. *The Journal of Biochemistry*. 2012;153(1):13-19.
23. Kim J-H, Ko P-W, Lee H-W, et al. Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. *Glia*. 2017;65(9):1471-1490.
24. Chapouly C, Tadesse Argaw A, Horng S, et al. Astrocytic TYMP and VEGFA drive blood–brain barrier opening in inflammatory central nervous system lesions. *Brain*. 2015;138(6):1548-1567.
25. Jiang S, Xia R, Jiang Y, Wang L, Gao F. Vascular endothelial growth factors enhance the permeability of the mouse blood-brain barrier. *PloS one*. 2014;9(2):e86407.
26. Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. *Biomolecules*. 2020;10(12).
27. Park J-C, Han S-H, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review. *BMB Rep*. 2020;53(1):10-19.